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Diabetic cystopathy results in a grossly distended, hypomotile bladder due to inefficient 
voiding.  While the bladder has been extensively studied, little effort has been made towards the 
understanding of the urethra and the effects of this devastating disease.  The current study is 
aimed to evaluate the effects of diabetes mellitus (DM) on the biomechanical properties and the 
pharmacological function of the female rat urethra ex vivo.  
DM was induced in female rats by injection of streptozotocin.  At 3, 5,and 10 weeks, the 
urethras were excised and mounted into an ex-vivo system at in vivo length. For mechanical 
testing, urethras were subjected to stepwise increases of static, intraurethral pressure from 0 to 20 
mmHg in both a baseline and passive state. Continuous outer diameter measurements were made 
using a laser micrometer at proximal, middle, and distal portions of the urethra. Compliance and 
beta stiffness were calculated from measured data. Pharmacological experiments involved 
assessments of mid urethral outer diameter response to Nω Nitro-L-arginine, phenylephrine, and 
EDTA. Age matched normal urethras served as controls. Statistical comparisons were made via 
ANOVA. Tissue was then processed for immuno- and histochemical quantification of smooth 
muscle, collagen, and elastin.  
 For baseline healthy tissue, results showed a proximal to distal compliance gradient 
(proximal most compliant and distal least compliant), and the passive state enhanced the 
observation.  Baseline beta stiffness values showed an increased stiffness in proximal and middle 
urethral portions by 5 and 10 weeks, and baseline compliance values showed at low pressures 
showed an increase in proximal compliance at 3 weeks and a decrease in proximal compliance at 
5 weeks at high pressures. Passive beta stiffness and compliance values indicated proximal 
urethral stiffening by 10 weeks DM.  Pharmacological studies revealed that DM abolishes 
 iv
endogenous nitric oxide release and increases the time to reach maximal relaxation. In cases of 
severe DM, alpha 1 adrenergic contraction was minimized.  Little or no differences were found 
in the amount collagen, smooth muscle, and elastin.  
 From these findings, it can be concluded that DM causes urethral stiffening and impaired 
contractile and relaxation urethral mechanism. Damaged urethral properties and function have 
serious implications for outlet resistance; thus, contributing to diabetic cystopathy.  
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1.0 INTRODUCTION 
 
 
 
 
 1.1 TYPES AND CLINICAL SIGNIFICANCE OF DIABETES MELLITUS (DM) 
 
 
It is estimated that 17 million Americans have diabetes mellitus (DM), according to the 
American Diabetic Association [1]. DM is a condition that involves abnormalities in the body's 
ability to use sugar [2]. In a healthy person, the pancreas makes extra insulin when they eat. 
Insulin helps move glucose in the bloodstream to the inside of cells where it is utilized as a key 
source of energy. A person with diabetes has the inability to produce enough insulin to keep up 
with their body’s demand, and the cells may resist the insulin; thus, glucose cannot be 
transported into the cells and used. 
DM is a disease of complex pathogenesis, which varies with one of three types, juvenile 
onset diabetes, diabetes mellitus, and gestational diabetes. Type I DM, otherwise known as 
insulin-dependent diabetes mellitus, involves a pancreas that makes little or no insulin. Type I 
diabetes is believed to evolve from an autoimmune disorder, in which the body produces 
antibodies that destroy pancreatic beta cells.  The cause of insulin dependent diabetes mellitus 
remains a mystery, yet genetics, age (usually occurs from spontaneous loss of beta cell function 
at approximately 11 to 14 yrs), and various viruses are suspected to play a role [3,4].  
 Type II DM, or non-insulin dependent diabetes mellitus, occurs when the cells in the 
body become resistant to insulin.  As a result, the body cannot consume glucose as well as it 
should.  This is the most common type of DM and risk factors consist of obesity, race, a 
sedentary lifestyle, high blood pressure, low HDL level, old age, and menopause.   
Similarly, gestational diabetes develops in some women during pregnancy, and in most 
cases, this condition will cease after childbirth [2,5].  Overall, long-term effects of this disease 
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involve profound damage to the circulatory system, nervous system, and other internal organs 
resulting in retinopathy, nephropathy, atherosclerosis, and neuropathy [2,3]. 
 
 
 
 
1.2  LOWER URINARY TRACT ANATOMY AND FUNCTION 
 
 
The act of micturition comprises of a storage phase and an expulsion phase, otherwise known as 
voiding. Micturition is dependent on the coordination of the bladder and the urethra both of 
which involve opposing function.  Essentially, the bladder acts as a reservoir for storing urine 
and as a pump for expelling it during voiding. On the other hand, the urethra remains closed 
during filling and controlled dilation provides a conduit for the urinary stream. The bladder and 
urethra are complex in structure comprised of highly innervated smooth or striated musculature 
[6]. 
 The bladder is composed of two basic elements: a body (detrusor) and a base (the 
trigone).  The body and base of the bladder are complex, interwoven meshes of smooth muscle 
fibers that lack discrete layers and are surrounded by collagen and elastin, blood vessels, and 
nerve axons or terminals. This organization allows the body of the bladder to accommodate 
increasing amounts of urine during the storage phase of micturition and the base of the bladder to 
form a vertical funnel to establish a conduit for urine during voiding [6,7].  
The urethra (Figure 1) consists of both an internal sphincter composed primarily of 
smooth muscle and an external sphincter composed primarily of striated muscle. Smooth muscle 
is found along the entire length of the urethra in the form of a thick inner layer of longitudinally- 
oriented muscle fibers surrounded by a thin medial layer of circumferentially-oriented muscle 
fibers.  The role of the different layers remains controversial.  Most commonly, it is believed that 
the circumferentially-oriented smooth muscle plays an important role in maintaining urethral 
pressure during filling and longitudinally-oriented muscle shorten and open the urethra during 
micturition.  Striated muscle, composed of both fast and slow twitch fibers, forms the outer layer 
of the urethra.  The striated urethral sphincter is thought to contribute largely to maintaining tone 
and high urethral pressure during the storage phase [8].  
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 Parasympathetic, sympathetic, and somatic innervations are responsible for successful 
storage and voiding.  Both sympathetic and parasympathetic nerve fibers innervate the bladder 
wall, more specifically the detrusor and the trigone.  Parasympathetic cholinergic fibers travel 
via the pelvic nerve to the bladder surface and elicit a smooth muscle contraction during the 
voiding phase of micturition by release of acetylcholine and activation of muscarinic receptors.  
Sympathetic noradrenergic innervation, which is present in the bladder, induces detrusor 
relaxation by release of norepinephrine and activation of beta adrenergic receptors. Somatic 
innervation is present in the external striated urethral sphincter and the pelvic floor muscles.  
Somatic innervation, provided by the pudendal nerve, transmits efferent cholinergic impulses to 
muscles of the pelvic floor, afferent signals from these muscles, and sensory information from 
the urethra [9]. Although the neural control of the female urethral smooth muscle remains 
uncertain, many studies have shown that urethral smooth muscle is densely innervated by the 
parasympathetic and sympathetic nervous systems. Sympathetic activity mediated through alpha 
adrenergic receptors contribute to the maintainence of high urethral pressure and resistance 
during the storage phase of micturiton; whereas, parasympathetic nerve fibers may contribute to 
urethral relaxation during voiding [8,10]. 
 
 
 
 
1.3 EFFECTS OF DM ON THE LOWER URINARY TRACT 
 
 
It has been stated in the literature that 52% of randomly evaluated diabetic patients were 
diagnosed with lower urinary tract dysfunction [11]. Still, it is difficult to estimate the portion of 
diabetic patients that suffer from urologic disorders, more specifically bladder dysfunction. 
While DM is a well-defined disease, diabetic cystopathy develops subtly and symptoms do not 
appear until the disease is in an advanced stage.  Moreover, methods of investigation and data 
collection lack a common criterion; thus, many investigators’ definitions of diabetic cystopathy 
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vary with factors, such as amount of residual urine, bladder capacity, and first sensation to void 
[12]. While treatments do exist, diagnosis and pathophysiology need to be better understood in 
order to more fully accommodate diabetic cystopathy.   
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 Voiding dysfunction is a common finding in patients with diabetes mellitus.  Usually, the 
first manifestation is impaired bladder sensation. Initially, symptoms are infrequent voiding, 
reduced stream, hesitancy in initiating the urinary flow, dribbling owing to overflow 
incontinence, sensation of incomplete emptying, and loss of the desire to void.  Diagnosis is 
established by the demonstration of cystometric abnormalities that are associated with residual 
urine.  For example, cystometrograms indicate decreased bladder sensation, increased bladder 
capacity, and areflexic or hyperreflexic bladders [13].  If addressed early, the condition can be 
reversed, but if allowed to develop without treatment, the chief complication is infection.  The 
presence of urinary retention inevitably leads to infection of the bladder.  Ultimately, the 
development of bacterial infection will reach the kidney leading to serious consequences, 
including renal failure [14].  
 Diabetic cystopathy is attributed to peripheral neuropathy affecting the somatic and 
autonomic nervous systems and leading to myogenic failure and the inability to mount a 
satisfactory detrusor contraction. Studies in human diabetes and in experimental animals suggest 
that the initial site of damage is the axon, which either provides input (afferents) or outputs 
(efferents) from a neuron. Segmental demyelination occurs which impairs conduction velocity 
and may result not only in temporary delay, but complete nerve blockade [13,15].  An 
electrophysiologic evaluation [16] performed on patients with DM showed decreased conduction 
velocities in patients with detrusor hyper-reflex or areflexia, which are defined as an overactive 
or non-contractile bladder, respectively.  The results of this study indicated the effects of 
segmental demyelination in the peripheral nerve supply in the bladder and proximal urethra.  
Other changes that have been found in diabetic neuropathy include alteration in the extracellular 
matrices surrounding peripheral. It has been found that circular Schwann cell basal laminar tubes 
occur following axonal degeneration and become crowded with densely packed collagen fibers, 
which are increased in diameter due to neuropathy also. These findings may play a major role in 
changes of the urethra and bladder since the extracellular matrix mechanically supports the 
surrounding cells and regulates their behavior through specific interactions mediated via 
molecules on the cell surface, such as integrins [17].   
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1.3.1 Effects of DM on the Bladder  
 
 
Human urodynamic studies have revealed instability of the detrusor muscle in the bladder wall 
with the onset of DM which progresses to increased cystometric capacity, decreased bladder 
contractility, and impaired urination [18,19].  Since the effects of DM on the lower urinary tract 
are time dependent, researchers have been motivated to study the damaging consequences of DM 
on the bladder at different time points, i.e. early and end stage intervals in animal models.  Early-
stage studies have shown that shortly after induction of DM using streptozotocin (STZ) 
treatment, diabetic rats display increased urine volume. While this study suggests that the 
bladder is changed to allow greater volumes of urine to be stored and passed, the detrusor muscle 
of the bladder did not display an impaired response to noradrenaline, acetylcholine, or 
cholinergic stimulation [20].  Additionally, Pinna et al. [21] showed that 4 weeks after the 
induction of STZ, the urinary bladder was significantly thicker and heavier and that the ATP 
contractile response was enhanced compared to controls. There was also no change in contractile 
response to acetylcholine. On the other hand, research examining the response of a 47 week STZ 
induced diabetic rat urinary bladder to autonomic stimuli, such as acetylcholine and 
phenylephrine, exhibited an increase of contractile response when compared to bladder strips of 
a 6 week diabetic rat [22].  Additionally, Moss et al. [23] examined the early and late effects of 
DM on an in vitro whole rat bladder preparation. Eight weeks after streptozotocin induction, 
cystometrogram showed an increase in bladder capacity associated with a decrease in 
intraluminal pressure, and an increased sensitivity to purinergic (receptors involved in contractile 
responses in the bladder [39]) agonists and a decreased sensitivity to cholinergic (receptor 
mechanisms which contract the bladder [39]) agonists.  In sixteen week cystometrogram, the 
bladder capacity had decreased and intraluminal pressure was within normal range, and a greatly 
reduced response to the purinergic agonists was detected.   
 
 
1.3.2 Effects of DM on the Urethra 
 
 
While there have been many studies emphasizing the effect of DM on the bladder, not much is 
known of the effect of this disease on the urethra.  The urethra is more than a simple conduit 
through which the urine exits.  Rather, it is a complicated structure which performs three 
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functions: a sustained tone to prevent urinary leakage during bladder filling, a transient reflex 
increased in pressure to prevent opening of the lumen when abdominal pressure rises, and a 
relaxation preceding micturition [8].  Understanding the effects of DM on this muscular organ 
may be key to solving problems of diabetic cystopathy.  One ex-vivo study scrutinized the 
response of DM on proximal urethral strips to pharmacological agents, such as ATP, 
norepinephrine (NE), and potassium chloride (KCL) [21].  DM appeared not to affect the 
contractile response to NE or ATP, but the contraction to KCL was decreased in DM compared 
to controls.  Another study set out to understand the short and long term effects of DM on the 
urethra [25].  While onset of DM caused an increase of micturition frequency and volume, 
findings showed substance P and vasoactive intestinal polypeptide concentration was somewhat 
higher in 6 week diabetic animals than in age-matched controls, but not statistically significant. 
These neuropeptides are found in sensory nerve fibers, and an increase in concentration may 
indicated changes in the bladder and urethra sensation. 
Using combined isolated isovolumetric cystometry and anterograde urethral perfusion 
pressure measurements, an in vivo experiment by Torimoto et al. [24] set out to identify and 
characterize alterations in physiological properties of the urethra from DM both during the filling 
and voiding phases. Results indicated impaired smooth muscle urethral relaxation mechanism 
during micturition in chronic DM rats, as well as a decrease of external urethral sphincter phasic 
firing and an increase in bladder pressure threshold for urethral relaxation. Consequently, this 
would be expected to reduce voiding efficiency during a period of diabetic cystopathy 
development.   
 
 
 
 
1.4 COMPARISON OF EXPERIMENTAL MODELS FOR URETHRAL BIOMECHANICS 
 
 
Typical urological signals, such as pressure and volume and their respective changes in time, are 
mechanical parameters.  The urethra maintains closure during increases in bladder pressure and 
volume during filling, characteristics of a load-bearing structure in which collagen and elastin 
may play a passive role.  Additionally, the smooth and striated muscle components of the urethra 
provide a urethral closure pressure, an active aspect of continence.  While no information 
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currently exists regarding the biomechanical impact of DM on the urethra, biomechanics has 
been used to characterize the bladder outlet in other types of voiding dysfunction. 
 
 
1.4.1 Importance of Studying Urethral Biomechanics  
 
 
 The ability to characterize fundamental mechanical tissue properties can be a powerful tool for 
understanding tissue function and determining origins of dysfunction and the progression of 
pathological disease states.  Only a few studies, which are summarized in section 1.4.2, have 
attempted to exemplify the fundamental mechanical tissue properties of the urethra, and the 
dearth of such studies may be attributed to the lack of appropriate experimental systems to 
perform them [41].  The utilization of experimental devices for other tissue such as the vascular 
testing systems of Vorp et al.[31] and Brant et al. [30], could produce a more thorough 
investigation of structure-function relationships for the urethra.  Such information is crucial to 
sufficiently address the role of biomechanics in urinary retention and incontinence as related to 
diabetic cystopathy.   
 
 
1.4.2 In Vivo Studies On Urethral Biomechanics  
 
 
 In the following studies, urethral biomechanical has been evaluated mostly to characterize stress 
urinary incontinence (SUI), an involuntary loss of urine secondary to an increase in abdominal 
pressure during events such as sneezing, coughing or laughing in the absence of bladder 
contractions. No studies known to date have concentrated on urethral biomechanics and DM in 
vivo clinically or in the laboratory. 
 
 
1.4.2.1 In Vivo Stress Relaxation Tests:     Utilizing a special probe developed for the 
measurement of intraurethral pressure and cross sectional area, Colstrup [42] described the 
rigidity (change in urethral pressure divided by change in cross sectional area) and urethral 
hysteresis (e.g. differential pressure at a given volume during inflation versus deflation) of 
different portions of the resting, healthy female human urethra.  The probe consisted of a 
polyvinyl catheter with a small balloon that was inflated with water and recorded values of 
 8
pressures and cross sectional area. Recordings were performed at 0.5 cm intervals from the 
bladder neck. The results showed that rigidity increased towards the mid and distal portions 
compared to the proximal portions of the urethra, indicating a rigidity gradient along the urethral 
length, proximal being the least rigid and distal being the most. In contrast, hysteresis varied 
little along the length. 
 This same technique was utilized to assess the value of a stress relaxation parameter 
(Pt0.5), which quantifies the dissipation of energy over time from the urethra in conjunction with 
surrounding anatomical structures stretched by urethral dilation, of healthy and stress incontinent 
women [43]. It has been found that muscle tissue tends to increase this parameter in comparison 
to connective tissue.  The measurements showed that Pt0.5 was significantly greater in healthy 
women than in women with SUI, with the greatest difference at the bladder neck suggesting SUI-
induced muscular damage or connective tissue remodeling.  
 
 
1.4.2.2 In Vivo Animal Model:      To quantify urethral wall stiffness for a normal urethra, Yalla 
et al. [44] used an in vivo female dog model.  The dog was anesthetized and the symphysis pubis 
was excised through a transpubic midline incision in order to expose the urethra. The goal of the 
study was to examine qualitatively the affects of urethral dilation, urethral myotomy, and tissue 
death on wall stiffness. The three different variables were assessed via changes in urethral 
infusion resistance and pressure-volume relationships.  A linear variable differential transducer 
measured changes in the external diameter of the mid urethra. The distal end of the urethra was 
occluded and continuous infusion of saline at a steady rate was allowed up to 200 mmHg. A 
polygraph continuously recorded diameter and pressure. This animal model suggested a non-
linear pressure-volume relationship, in general for all tissue. Urethral dilation was found to 
increase compliance (i.e. pressure-volume curves shifted to the right of normal urethral response 
curves) and slowed the rate of stress relaxation. Urethral myotomy increased compliance, and 
dead tissue exhibited increased compliance and a slower rate of stress relaxation.  This model 
was able to demonstrate qualitatively the general biomechanical behavior of urethral tissue in 
three different states, but no quantitative data (e.g. beta stiffness indices, etc.) were derived.  
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1.4.2.3 Limitations of These Studies:     While these in vivo models, described in Sections 
1.4.2.1 and 1.4.2.2, initiated biomechanical studies of the urethra, there are several limiting 
disadvantages to their techniques.  The study by Colstrup considered that the urethra was not 
homogeneous and measured rigidity alongth the entire length of the urethra, but Yalla et al. 
neglected this issue and concentrated primarily on the mid portion of the urethra only. On the 
other hand, the dog model could not provide the researchers with the ability to look strictly at the 
urethral biomechanical properties since the urethra was still attached to the vaginal wall, and the 
human model could not discriminate the urethra from peri-urethral structures. If the parameters 
(infusion rate, volume of fluid, etc.) were identical for both studies, it would have been 
interesting if one could correlate the two studies. Also, studies by Yalla et al. only demonstrated 
qualitative endpoints, and neglected to quantify compliance or stiffness in the different urethral 
states.  
In addition, the Colstrup study did not randomize the points at which the urethra was 
tested. Although these experiments were performed in vivo, consistently evaluating 
biomechanical properties in the same order (bladder neck, mid portion, then distal portion, for 
example) may have biased the results. Also, intramural hemorrhaging and edema in the dog 
model may have created uncontrolled variables, such as spontaneous urethral dilations or wall 
thickening. Both studies lacked histological or immunohistological evidence of tissue structure 
and function relations to their results.  Finally, the size of the balloon catheters and infusion rates 
used could have a variable affect on the biomechanical results of these studies and physiological 
pressures were not used (150 and 200 mmHg).  
 
 
1.4.3 Ex Vivo Assessment of the Urethra Using Whole Mount Urethral Models 
 
 
Research to date, has shown little effort to explore urethral biomechanics with the use of whole 
mount ex vivo studies. Mayo and Hinman [45] utilized an ex vivo model to demonstrate that the 
female urethra is anisotropic, i.e. the circumferentially-oriented muscle and connective tissue 
fibers have a decreased compliance compared to longitudinally-oriented ones.  The model 
involved excision of a 3 cm segment of a female dog urethra between the bladder neck and the 
pelvic floor. The urethra was marked with sutures to carefully maintain in vivo length.  One end 
of the urethra was tied over a glass tube, and a silk thread to the central core of a differential 
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transformer attached the other end over a low friction pulley where 0.5 g of tension was applied 
to balance the urethra. The differential transformer (length transducer) provided a linear response 
and could be calibrated to read to 1 or 2 cm full scale.  A 50 ml bath of Locke’s solution was 
oxygenated and circulated for a physiological environment. A static pressure reservoir filled with 
Locke’s solution was used to apply intraluminal pressure. Pressure was measured at a point 
between the graduated scale and the specimen via a strain gauge transducer.  
While this study presented useful information on the anisotopic nature of the urethra, 
only a 3 cm segment was used, and not the entire organ. It would have been appealing to 
establish whether inclusion of the distal end would have made a difference in their results.  They 
also allowed the urethra to fully collapse (longitudinal contraction) after excision of the urethra 
and before restoring it back to in vivo length. This may have impaired the integrity of the tissue. 
Finally, this study lacked histological or immunohistological evidence of tissue structure and 
function relations to their results. 
Another study that utilized a whole ex vivo mount model [26] used rabbit urethras, which 
were excised and ligated to a j tube at the distal end and a catheter at the proximal end. The 
catheter was connected to a three-way stopcock, which enabled a transducer to measure pressure.  
The diameter measurement was based on increase of pressure at one point proximally which was 
measured by a transducer output to a grass polygraph recorder.  While this was a clever indirect 
means of measuring the diameter, it was not as accurate as other established techniques (e.g. 
helium-neon laser micrometer).  Also, the experimental system provided continuous flow of 
saline intralumenally (1 ml/min) via an infusion pump.  With only one measurement proximally 
to the urethra and the distal measurement absent, there was no way of knowing if there was a 
pressure drop over the urethral length. Of course, the study could have assumed that the flow was 
minimal enough that it did not pose a differentiating factor.  
 
 
1.4.4 Ideal Biomechanical Studies for the Urethra 
 
 
Ex vivo observations allow examination of urethral tissue without potentially confusing effects 
of the surrounding muscular and other support structures.  Urethral strip studies or divided ring 
segments dominate the small amount of literature dealing with ex vivo studies which examine 
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pathological states, like DM.  Yet, whole mount urethral preparations provide advantages over 
the segmented tissue models. These preparations provide the three dimensional geometry without 
any muscle fiber damage that would result from yielding urethral strips or sectored rings.  
Additionally, the physiological intraurethral pressure may be applied to understand the 
biomechanical response of the urethra, and the pharmacological function may be understood 
with the heterogeneous nature of the tissue intact.  
 An ideal tool to study any changes that may occur in the urethra must have certain 
attributes. First, unlike any of the systems previously described in Section 1.4, the ideal ex-vivo 
system would more closely mimic the in vivo environment.  Second, it is important to have the 
ability to separate the urethra from affecting factors, such as biochemical agents released in the 
body and surrounding structures. Thirdly, the three dimensional geometry must be preserved to 
account for the fact that the urethra is a heterogeneous complex conduit. Finally, the 
experimental arrangement must allow for all portions, i.e. proximal, middle, and distal, of the 
urethra to be assessed for gradients of pharmacological responses or material properties without 
severing any juxtaposed segments not of interest.  
 
 
 
 
1.5 ANIMAL MODELS FOR DM INDUCTION AND URETHRAL BIOMECHANICS 
 
 
When considering an animal model for examining any pathological state, the investigator must 
control for a wide array of variables, such as age, hormonal status, sex, strain, and habitat. Some 
previous types of animal models used for diabetes are alloxan injection [3,69,79,85] and NOD 
mice [3,85] and BB Wistar rats [3,85] where the pancreatic beta cells are spontaneously 
abolished upon birth. While the diabetogenic effect of STZ is more reproducible and less 
influenced by changes in the nutritional status of the animals, the metabolic changes are closer to 
those existing in human diabetes than the response of alloxan (a drug that completely eliminates 
the pancreatic function) induced diabetes [47].    For this study, the female rat offers an 
inexpensive and versatile species to investigate the effects of DM on the urethra.  While neural 
pathways are less complex than that of humans, nevertheless, the female rat lower urinary tract 
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closely replicates that of the female human.  Certain important issues of this animal model are 
discussed in the following sections. 
 
 
1.5.1 Comparisons of the Rat Lower Urinary Tract vs. Human Lower Urinary Tract 
 
 
While the rat offers an important animal model to induce DM and subsequently investigate 
bladder and urethral function, this animal model does have certain differences in the lower 
urinary tract from the human.  These differences deal with transmitter mechanisms and 
coordination of voiding [32]. Pharmacological evidence suggests that adenosine triphosphate 
(ATP) may be the transmitter responsible for atropine resistant bladder contractions, but, on the 
other hand, humans hold a small component of atropine resistance, which is also independent of 
neural firing.  
As for the coordination of voiding, lower urinary tract of the adult rat displays reflex 
bladder contractions that occur simultaneously with rhythmic contractions of the external 
urethral sphincter (EUS). Rhythmic contractions of the EUS have been thought to promote 
voiding by creating a urethral pumping action or by inducing temporary isometric contractions of 
the bladder [10]. However, this characteristic of voiding is reminiscent of detrusor sphincter 
dyssynergia, which is the loss of coordination of the bladder and its outlet, observed following 
lesions of the spinal cord in humans.   
 
 
1.5.2. Female versus Male: Anatomical Considerations 
 
 
As mentioned previously, the lower urinary tract anatomy of the female rat has proven to be a 
useful model for studying pathology induced changes in lower urinary tract function. Although, 
the male has also been used for to evaluate genito-urinary tract disorders with studies such as 
urethral reconstruction, erectile dysfunction, and effects of DM,  the female rat lower urinary 
tract was more suitable both experimentally and anatomically for present studies. 
 The rat male genito-urinary tract (Figure 1.2) basically consists of bladder, ureters, 
urethra, vas deferens, bulbourethralis, and the prostate.  Many of these elements may cause 
problems for the experimental set up. For example, biomechanical and pharmacological data are 
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based on outer diameter measurements; thus, in vivo length must be maintained since the 
diameter is largely dependent on its length. That is, if the urethra is stretched further than its in 
vivo length, biomechanical data will be skewed and any diameter response from 
pharmacological agents will be smaller.  In the male urethra, it would be difficult to maintain in 
vivo length. The lumen of the urethra drastically varies in segments ranging from large (e.g., 
proximal urethra) to exceptionally small sizes (e.g., the prostatic urethra).  These varied 
segments make it difficult to use one appropriate sized catheter to insert into the lumen, and it is 
crucial to match up the size of the catheter with the inner diameter of the lumen to avoid any 
collapsing of the tissue, which would damage the urothelium.  Also, since the prostatic urethra is 
extremely tiny in diameter, it can damage very easily when surgically manipulated. 
 In the female, the ureters are tubes leading to the bladder neck, which need to be tied off 
to prevent leakage and serve as anatomical landmarks for in vivo length.  Since the ureters are 
located at the bladder neck, suture ligations will not affect the integrity of the urethra, nor skew 
any outer diameter data. Despite the fact that the ureters and the vas deferens can be sutured in 
the male urethra, there still remain tiny tubes leading to the bulbourethralis, which will need to 
be ligated.  Since the urethra is so small in diameter, and the locale of these tubes are at a 
midpoint along the urethra, these ligations would have a major affect on any deformations that 
are a result of applying static pressure and would ultimately affect the biomechanical properties. 
This could also pose a problem for measuring the outer diameter with the laser micrometer. 
 Finally, one last consideration that deals with muriform rodents entirely is the vaginal 
plug that is present within the male pelvic urethra.  This anatomical component resides in a 
rather vacuous (relative to the rest of the urethral diameter) outpouching that runs the length of 
the post-prostatic and pre-penile urethra.  Moreover, there are many conduits that make large 
holes along the length from which the prostatic and seminiferous tubule secretions pour in to 
solidify and form the eosinophilous, proteinaceous, solid, sperm shuttle. Also, the prostatic 
urethra could potentially serve as the proximal tying off point, but it is thin and weak and could 
easily be damaged.  As well, the urethra exiting the pelvic floor makes a sharp, perpendicular 
turn to become fairly the rigid, spring-loaded penis where most mammals, other than humans, 
have penile bones or at least rigid cartilage, and at this juncture lies a diverticulum.  Therefore, 
the muriform urethra with its specialized sperm delivery system makes it quite difficult for 
urethral biomechanical studies using this experimental set up.   
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Figure 1.2: Depiction of the lower urinary tract of a male muriform rodent. The female 
muriform rodent lower urinary tract is more comparable to that of the female human. 
Adapted from www.uscd.edu/jpathology 
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A.6 SCIENTIFIC OBJECTIVES AND HYPOTHESES 
 
 
One of the main outcomes of DM is autonomic neuropathy, which can greatly affect the urinary 
bladder and the urethral sphincter.  While it is clear that many urinary problems occur 
due to neurological complications, it is also important to evaluate any structural changes to the 
connective tissue and smooth muscle from diabetes mellitus.  The diabetic bladder has been 
widely studied; yet, understanding the affects of DM on the urethra may be key to solving 
problems of diabetic cystopathy.   
 Therefore, the objective of this thesis was to evaluate the effects of DM on the urethral 
biomechanical properties and pharmacological response of the female rat urethra ex-vivo.  
Employing techniques discussed in Section 1.5 [87], the biomechanics and smooth muscle 
function of diabetic rat urethras at three different time points after the onset of induction of 
diabetes mellitus (3, 5, and 10 weeks) were compared to healthy age-matched controls.  These 
studies were performed in three different states: passive, active, and baseline. 
 
The Hypotheses that were addressed in this project are: 
 
1) DM urethras are stiffer (less compliant) when compared to healthy controls, and these 
changes are due to an alteration of tissue musculature and connective tissue 
components. 
2) The pharmacological response of DM urethras is impaired in comparison to that of 
healthy control urethras. 
 
The Specific Aims executed to evaluate these hypotheses were: 
 
1) A. Experimentally determine the compliance and beta stiffness values of the urethra 
for normal and DM rats. 
B. Perform histological analysis to assess the possible differences of musculature and 
connective tissue among healthy and DM urethras. 
2) Compare measurements and observations from 1) A. and B. for  three different states, 
passive with tone, active, and passive without tone, among DM and healthy controls 
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3) Measure contractility and relaxation of the healthy and DM urethras in response to 
pharmacologic stimulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 17
  
2.0 METHODS 
 
 
 
2.1 DM INDUCTION AND URETHRAL HARVEST 
 
 
DM was induced in female rats by intraperitoneal injection of streptozotocin (STZ) at a 
concentration of 65 mg/kg, which is a standard protocol [85]. STZ abolishes beta cell function of 
the pancreas, which ceases insulin production, a trait common in patients with DM [38].  
Previous to tissue removal, blood sugar was assessed. Rats were considered diabetic with levels 
above 300 mg/dl.  At three different time points following STZ treatment (3, 5, and 10 weeks), 
animals were anesthetized with urethane (1.2 g/kg), and the urethra was immediately excised.  
An intraluminal catheter was inserted into the urethra, and an incision at the apex of the bladder 
dome was made, and the bladder was ligated, as well as the distal external meatus.  The ureters 
were tied off to prevent leakage and to serve as anatomical landmarks for in vivo length 
measurement, which were made prior excision. The maintenance of in vivo length is important 
since each animal will have a different sized urethra; thus, all tests were standardize by keeping 
each specimen at its own specific in vivo length.  For transport, urethral specimens were then 
placed in media 199 that was bubbled for a minimum of 30 minutes with a gas mixture (95% 
oxygen and 5 % carbon dioxide) in order to prevent anoxia. 
 
 
 
 
2.2 EX VIVO URETHRAL TESTING SYSTEM 
 
 
The idyllic factors stated Section A.5 served as motivation for the modification of an existing ex 
vivo vascular testing system [26,42-45] in order to test intact urethras both biomechanically and 
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pharmacologically [87].  The resulting new urethral testing system [87] is described in this 
Section.  
 
 
2.2.1 Static Pressure Measurements 
 
 
System modifications were required in order to accommodate the urethral tissue.  Several 
constraints were considered when making alterations.  First, the system previously had been used 
to mimic the arterial environment, with applied pressures of 100 mmHg or more, as well as the 
application of pulsatile pressure.  For the rat urethra, the maximum pressure experienced is 
approximately 25 mmHg [28], and flow is not continuous, but rather intermittent during time of 
voiding.  Thus, it would be appropriate to apply hydrostatic pressure and ignore the effects of 
flow.   
 In these studies, stepwise pressure was held constant. Therefore, it was appropriate to 
measure pressure at one location and this was achieved just proximally to the urethra (Figure 2.1 
and 2.2) via a strain gauge transducer (model #: PX272, Baxter Healthcare Co.), which output a 
signal to a pressure monitor (Model #: 90603A, Space Labs Inc.).  Pressure was applied by 
clamping off the distal tubing (i.e. the exit for the urethra) and by utilizing a hydrostatic pressure 
reservoir attached to a graduated ring stand.  The reservoir was manually displaced to establish 
graduations, which were calibrated by a manometer for intervals of 2 mmHg using the pressure 
height relation.  
Equation 2.1:          p-p0 = ∆p = ρgh 
 
The range of intralumenal pressure applied was 0 to 20 mmHg.  As for the working fluid, which 
was cell culture media, the density was taken as ρ=ρH2O= 1000 3m
kg . For a change an 
imcremental change in pressure of 2mmHg, the change in height (h) necessary was calculated as 
2.7 cm. The applied intralumenal pressure was continuously recorded via computer. 
2.2.2  Measurement of Outer Diameter  
 
 The outer diameter of the urethra was measured using a helium-neon laser micrometer 
(laser Model # 162-100, Beta Lasermike) [30]. The laser emits monochromatic light at 632.8 nm 
and has a scanning range from .254 to 50 mm (+/- .01 mm accuracy).  A urethra is placed in the 
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path of the beam preventing light from reaching the photocell opposite the emission source 
(Figure 2.1 and 2.2). Using the time interval for a scanning segment and sweep velocity (9800 
cm/s), the laser calculates the blocked distance (i.e. the outer diameter).  Analog laser voltages 
are digitized through a 16 channel A/D converter in order to output the measurement to the 
computer (Pentium II 266 MHz) where it continuously records the data 27,29,30. The laser 
micrometer is calibrated with the use of precisely machined tubes of known diameter. 
 
 
2.2.3  Components of  the Ex Vivo Perfusion System 
 
 
Due to the small size of the urethras, specially fabricated attachment/infusion tees with an outer 
diameter of approximately 1.25 mm were used.  Pressure ports were attached to the tees with 
transparent polyethylene tubing (3/16” inner diameter).  The tissue housing chamber (Figure 2.1) 
was composed of plexi-glass with glass windows inserted into the side panels.  The glass 
windows are offset at 5° to minimize diffraction of the laser that scans through the chamber for 
the purpose of diameter measurement [31]. The lid to the housing chamber consisted of plexi-
glass with a gas exchange port attached to the top.   
 It is important to maintain physiological pH of 7.4 and temperature of 37°C.  Media 199 
(Sigma Chemical Co., #M3769) was used for the adventitial bath to provide nutrients to the  
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Figure 2.1:  A schematic of the modified ex vivo urethral testing system 
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Figure 2.2: A photograph of the entire testing system (top), and a female rat urethra 
mounted onto the attachment/infusion tees (bottom).  The urethras tested had an average 
length of approximately 20mm. 
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specimen.  This was continuously circulated through a heat exchanger and water bath (Model #: 
13000, Lab-Line instruments)  by way of a roller pump (model #: 7553-20, Cole Parmer 
instrument Co).  A blood gas mixture (Nationally Valley Gas), consisting of 74% nitrogen, 21% 
oxygen, and 5% carbon dioxide was directly bubbled into the bathing and reservoir medium in 
order to maintain physiologic gases.   
 
 
 
 
2.3 BIOMECHANICAL TESTING 
 
 
In order to assess the affects of DM, biomechanical and pharmacological tests were used. 
Biomechanical tests were executed in two separate states, baseline and passive.  Baseline tone 
refers to a tissue state in which no attempt was made to either stimulate or eliminate contraction 
of either muscle component, and passive tone is used to describe the state in which induced 
muscle contractions, as well as any endogenous tissue tone was eliminated. Pharmacological 
evaluations were performed to assess alterations to smooth muscle function caused by DM.  In 
this section, the methodology utilized for these measurements is described.   
 
 
2.3.1 Parameters for Biomechanical Studies 
 
 
Before performing our biomechanical studies, it was first necessary to establish two testing 
parameters:  the maximum number of cycles needed for preconditioning (i.e. to obtain a 
repeatable curve) and the duration of each step of pressure.  Initially, specimens were 
preconditioned between 0 and 16 mmHg. The range was decreased to between 0 and 8 mmHg 
because it was felt that the higher pressure of 16 mmHg might disrupt the muscle fibers, which 
would skew any biomechanical properties.  It was determined that 6 to 7 cycles of this 
pressurization was sufficient to obtain a repeatable curve (Figure 2.3). 
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Figure 2.3 : The above picture represents the results of the preconditioning regimen of the 
middle region for a female rat urethra in the baseline state.  The dotted line indicates the 
diamet  of the urethra after the first cycle’s pressure step, illustrating the change in peak 
diameter over from the first cycle to the tenth.  Note that by the sixth or seventh cycle the 
cycles begin to appear repeatable. 
 
 
 
Similarly, preliminary step experiments were performed in order to determine the 
duration needed for the diameter measurement to become stable after each 2 mmHg increment of 
pressure.  This was completed by holding each pressure for a duration of 1.5 minutes and 
bserving the extent to which the diameter became constant.  From Figure 6, one may see that 
e diameter did reach a constant value at lower pressures as soon as 1 minute after application, 
ut this held true only for pressures up to approximately 6 mmHg.  Beyond this pressure, the 
iameter remained constant for 2 minutes and increased a minimal amount (roughly less than 
%) by the end of the 1.5 minute interval.  Thus, the time parameter for each step in the static 
ressure experiment was a 1-minute interval.  
er
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igure 2.4:  Top: The pressure profile for a static pressure experiment holding each 
crement of pressure for 5 minutes. Bottom: The resulting outer diameter measurement 
r the proximal portion of a female rat urethra. 
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2.3.2 Baseline Biomechanical Studies 
 
 
Upon arrival to the laboratory, specimens were mounted onto the tees of the ex vivo testing 
system described in Section 2.1. The hydrostatic pressure reservoir was manually displaced 
about the calibrated ringstand in order to apply intraluminal static pressure. First, the tissue was 
preconditioned as described in Section 2.2.1 (Figure 2.3).  Next, the urethra was subjected to the 
step experiment described in Section 2.2.1 (Figure 2.4).   
Due to the fact that the tissue is non-homogeous, measurements were taken at three 
positions along the length (L) of the urethra (Figure 2.5):  the proximal (a distance of L*0.3 from 
the proximal end of the specimen), middle (a distance of L*0.5 from the proximal end of the 
specimen) and distal (a distance of L*0.7 from the proximal end of the specimen) positions.  
 
 
 
        
 
 
 
 
 
 
 
n the in actual measured 
d to be the length of the urethra. 
  
  
 
Figure 2.5:  Schematic depicting the identification of the three positions used for 
measurement along the length of the urethra. L was taken as 3mm less than  the measured 
in vivo length.neck, the value of ‘L’ used here was 3mm less tha
vivo length. L was actually considere
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It should be noted that in order to take into account that the ureters are integrated wit
bladder. From the pressure and diameter data gathered, compliance (C; equation 2) and 
stiffness [34] (β; equation 3) values were calculated to quantify the biomechanical properties o
the urethra.   
     Equation 2.2 :               ( DD −
h the 
beta 
f 
 
 
 
 
     Equation 2.3: 
 
 
 
  
 
C, is the fractional change in volume that occurs in response to changes in pressure where Dmax 
and Dmin represent the measured diameters corresponding to the maximum and minimum 
pressures, Pmax and Pmin, used to define the range over which the compliance is calculated.  The 
incremental compliance was evaluated for the following pressure ranges: 0-6 mm Hg, 6-12 
mmHg and 12-18 mmHg. This approach permitted correlations of differences in biom hanical 
ehavior with tissue microstructure [88].  Beta stiffness,β, is a dimensionless parameter which 
ay be utilized to describe non-linear pressure-diameter responses and incorporates all pressure-
 
 to 
at a mid point of the 
physiological range, it was chosen as Ps for this experiment. 
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diameter values over the range of physiologic pressure examined. Ps and Ds are a standard
pressure and paired corresponding diameter, respectively, which is chosen by the investigator
be within the average physiologic pressure range. Since 10mmHg fell 
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2.3.3 Passive Biomechanical Studies 
 
 
Studies on the biomechanics of the passive urethra were performed in the same manner as for the 
aseline studies described in Section 2.3.1 with the exception of the addition of 3mM 
thylenediamine tetraacetic acid (EDTA), a calcium and magnesium chelator, into the bath with 
 syringe. The incorporation of this agent occurred prior to mechanical testing and the tissue was 
llowed to equilibrate for 30 to 45 minutes in order to ensure that muscle contractions were 
ompletely blocked and the tissue is completely passive. Compliance and beta stiffness were 
calculated and quantified as in Section 2.2.2. 
 
 
2.4 PHARMACOLOGICAL ASSESSMENT OF URETHRAL SMOOTH MUSCLE 
FUNCTION 
 
tetraacetic acid (EDTA), a calcium 
helator, (n=6-9).  Specifically, % ∆D was calculated as:  
b
e
a
a
c
 
 
 
 Tissue responses were measured at the middle portion of the urethra following addition of 
muscle agonists or antagonists for both healthy urethras and urethras after 5 and 10 weeks of 
DM.  For these experiments, the urethra was exposed to a fixed intraluminal pressure of 8 
mmHg, which caused the tissue to be pre-dilated and allowed for a measurable amount of 
contraction to take place.  Upon pressurizing the urethra at 8 mmHg, 30 minutes was allowed in 
order for the specimen to reach a baseline diameter (D8mmHg ).  This measurement allowed the 
determination of the relative percentage change (% ∆D) in outer diameter, following the addition 
of muscle-responsive agents, added consecutively: 100µM [36] Nω-Nitro-L-arginine (NLA), a 
nitric oxide synthase (NOS) inhibitor; 40 µM [35]  phenylephrine (PE), a nonselective alpha-
adrenergic receptor agonist; and 3 Mm [37] ethylenediamine 
c
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   Equation 2.4: 
 
 
 
where Ddrug represents the diameter response to each respective pharmacologic agent, and 
D8mmHg  is defined as the baseline diameter measured at an intralumenal pressure of 8mmHg prior 
to addition of any pharmacological agents.  In order to ensure full effect on the urethra, a time 
interval of 20 to 30 minutes was permitted after administration each pharmacologi
%100%
8
8 ×


 −=∆
mmHg
mmHgdrug
D
DD
D
cal agent, with 
e exception of EDTA where the interval was increased to 30 to 45 minutes to ensure the fully 
assive state for biomechanical testing. 
At the time of pressure application or drug addition, the pressure was measured from the 
transducers and the diameter was taken as an average of the last 100 diameter data points 
record  
aximal diameter response to 8 mmHg, NLA, and EDTA.  Both the maximum magnitude of 
ontraction (PE-Max) and the magnitude of contraction value just before addition of EDTA (PE-
End) was calculated for diameter response to PE.   
 
 
 
rose solutions of, 10%, 20%, and 
0% sucrose in PBS, which served as a ‘cryoprotectant’ to the tissue.  Histological assessment 
as performed in order to examine and quantify the microstructure; more specifically the 
ollagen, elastin, and smooth muscle components. Alterations to these constituents were 
compared to the results of the biomechanical and pharmacological data.  For example, an 
th
p
ed before the addition of the next drug.  Calculations for % ∆D were performed for the
m
c
 
 
2.5 MICROSTRUCTURAL ANALYSIS 
 
For immunohistological and histological evaluation, upon the termination of experiments, 
urethras were removed from the experimental testing system, re-tied onto the intraluminal 
catheter at in vivo length, and placed in 10% formalin in phosphate buffered saline (PBS) 
overnight. Specimens were then subjected to ascending suc
3
w
c
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increase in stiffness of DM tissue may be a result of an increase in collagen present, or 
onversely, a decrease in elastin.  The following sections describe the methods used for 
icrostructural analysis of all urethral specimens studied. 
tified with smooth muscle alpha actin antibody staining.  
Alpha a
Section 2.2.2.  Each section was placed vertically into a cryomold and saturated with TBS 
 frozen in liquid nitrogen in order to avoid 
any deterioration of the tissue due to ice crystal formation.  Next, 8 to 11 µm cross sections of 
the proximal, middle, and distal portions of the urethra were cut with a cryostat 
Therm shandon) and placed onto gel-coated slides to increase the adherence of the section to 
the slides.  Each section was circled with PAP-pen, a hydrophobic marker.   
 Prior to immunohistochemistry, the tissue was fixed in 2% paraformaldehyde for 1 hour 
t room temperature. Goat serum was used to block any non-specific protein binding (45 
:100 
n 
 on 
 
c
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2.5.1  Identification of Smooth Muscle 
 
 
Quantifying the smooth muscle may aid the understanding any impairment of urethral smooth 
muscle function due to DM. Both smooth muscle types, i.e. longitudinally- and 
circumferentially- oriented, may be iden
ctin is a cross-linking protein, which helps to form a loose contractile bundle of actin 
filaments. This protein is concentrated in stress fibers in contractile bundles of the smooth 
muscle.  Thus, this method is suitable for specifying smooth muscle in the urethra.   
 First, urethras were divided into proximal, middle, and distal portions as defined in 
freezing medium (Fisher Co) where it was then snap
( o
a
minutes).  Primary antibodies (Chemicon) for the smooth muscle alpha actin were diluted 1
with bovine serum albumin (BSA) and left on the sections for 1 hour. Subsequently, the 
secondary antibody for fluorescence, TRITC, was placed on the sections for another hour i
dilutions of 1:200 with BSA.  Finally, for a secondary stain of cell nuclei, Hoescht was placed
the sections for 15 to 30 seconds. All slides were coverslipped with gelvatol and protected from
light. All washes between steps were performed with PBS and BSA.   
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2.5.2  Identification of the Connective Tissue 
  
 
Collagen and elastin are the two major connective tissue matrix proteins that were quantified in 
ining methods were used to designate each protein.   
The tissue was embedded and prepared for microscope slides in the same manner as in 
 
ing in a high 
 
as used for 
 minu cid 
, 
n 
sin. The tissue 
 
anate (Aldrich, 
at 
 
Pictures were taken of each circular section using a fluorescent (immunostaining; Nikon Eclipse, 
odel E800, Tokyo, Japan) and light (histological stains; Olympus, model BX51, Japan) 
ns along the circumference, i.e., at the 12 o’clock, 
3 o’clock, 6 o’clock, and 9 o’clock positions. Smooth muscle was identified by the red 
fluorescence emitted by the Tritc secondary antibody. Collagen was identified by the blue color 
this study. Two separate histological sta
 
Section 2.5.1 with the exception that sections were 20 µm thick, and slides were not gel coated.
(The gelatin coated slides were found to non specifically bind to the stains result
degree of background staining.)  For collagen, Masson’s trichrome stain was used.  First, slides 
were placed in Bouin’s solution overnight at room temperature. Slides were washed in running
tap water and kept in Weigert’s hemotoxylin (Sigma Chemical Co.) for 5 minutes.  After 
washing in running tap water, Biebrich scarlet-acid fuchsin (Sigma, #HT-151-250) w
5 tes, and a wash with deionized water followed.  Phosphomolybdic/phosphotungstic a
(Sigma, #224200 #P0550) solution prepped the sections for the aniline blue solution (Sigma
#41,504-9).  Slides were then submerged in 1% acetic acid solution for 5 minutes, dehydrated i
ascending alcohols (95% and 100%), cleared in xylene, and coverslipped with gelvatol.   
 Elastin was differentiated from collagen by using Weigert’s resorcin fuch
was prepared for microscope slides in the same manner as for the collagen stain.  First, sections
were hydrated with tap water, then subjected to acidified potassium permang
#31,941-4), 1 % oxalic acid (Sigma, #O-0376), and 70% alcohol, sequentially.  Next, the 
sections were stained in Weigert’s resorcin fuchsin (Sigma,#R-5645; Aldrich, #85,734-3) 
room temperature followed by a differentiation step in acid alcohol. Finally, slides were 
dehydrated with ascending alcohols, cleared in xylene, and coverslipped.    
 
2.5.3 Quantification of Tissue Constituents 
 
 
m
microscope at 20x magnification at four positio
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and elastin by its deep purplish black color. Smooth muscle, collagen, and elastin were 
separately quantified using Bioquant Nova software (NOVA 4.00.8 for Windows 98, vol.1581, 
2.6 STASTICAL ANALYSIS 
 
or both baseline biomechanical studies and passive biomechanical studies, three different time 
points were compared to healthy controls.  Statistical analysis was performed with Sigma Stat 
Software (Aspire Software Int., Leesburg, VA) using a one-way analysis of variance (ANOVA) 
with repeated measures to compare the compliance and beta stiffness values of the portions (i.e., 
proximal, middle, and distal) within the specimen. A one-way ANOVA was used to compare 
each portion separately among time points and healthy controls.  Finally, a two-way ANOVA 
was used to evaluate which factor played a larger role in any differences, onset of DM (i.e. DM 
vs. control), positions within the tissue, or both.  
Nashville, TN). The software measured the area for each portion of interest based on their 
respective colors and exported this data to a Microsoft Excel workbook where it was 
subsequently analyzed. The total area of the section was also measured. The total areas 
calculated for the four clockwise positions were added for total area (Atotal), and the amount of 
stained areas for collagen, elastin, or smooth muscle was added together in the same manner 
(Astain).  The percentage of each component (Astain%) was then calculated by:   
 
   
Equation 2.5: 
 
 
%100% ×


=
total
stain
Stain A
AA
An average was taken between two separate sections for each position for all specimens, so that 
each of the three constituents of interest were expressed as a percentage of total area.   
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For pharmacological data, as well as tissue constituent data, one way ANOVA wa
analyze whether there were any differences between controls, 5 and 10 weeks DM at
position. A Student Newman Keuls test was used for post-hoc testing.  
 
 
 
s used 
 the middle 
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3.0 RESULTS 
 
3.1 THE DIABETIC RAT MODEL 
 
 
Approximately three weeks post-STZ injection, male rats began to show 
rapid weight loss and emaciation, but this characteristic did not hold true for all animals injected 
with STZ.  Some of the animals did not show this characteristic until after 6 weeks post-STZ 
injection.  Other than high blood sugar (Figure 3.1), anatomical features of diabetic rats exhibited 
large bowels, largely distended urinary bladder, little surrounding adipose tissue, soft fecal 
matter, and enlarged ureters and urethras.   
 
 
 
 
3.2  BIOMECHANICAL STUDIES 
 
 
3.2.1 Baseline Biomechanics  
 
 
ll urethras, whether DM or healthy, had non-linear, sigmoidal pressure-diameter curves which 
 characteristic of biological tissues.  Such data is a useful indication of tissue compliance or 
istensability, with a leftward shift of the pressure-diameter curves indicating a decrease in this 
roperty.  Averaging all pressure-diameter data of healthy controls indicated a trend of a 
roximal-to-distal compliance gradient, proximal being the most compliant and distal being the 
least (Figure 3.2). Comparing the averaged pressure-diameter response curves of DM and 
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healthy urethras suggests that proximal 3-week DM urethras are more distensible than control 
nd 5 and 10-week DM urethras (Figure 3.3).  While this trend seemed to hold for middle 
portions, the control distal portion was less distensible compared to all three time-points of DM. 
 
 
 
    
igure 3.1:  Blood glucose levels of DM rats compared to healthy controls 
 
 
 
a
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 35
 36
 
 
f 
 
 
 
 
 
 
 
 
 
Figure 3.2: The average pressure-diameter data for 11 healthy urethras in the baseline     
condition. Note the proximal to distal stiffening effect as indicated by the leftward shift o
the curves. 
 
 
 
  
Figure 3.3: Average pressure-diameter response of proximal (top), middle (middle) and 
distal (bottom) portions of DM urethras and controls in the baseline state.  
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 As one general comparison, the 3-, 5-, and 10-week DM urethras were combined into a 
single group of DM data (n=31) and compared to healthy controls (n=11) for both the baseline 
and passive states.  For low-pressure (0 to 6 mmHg) incremental compliance, the proximal 
portion (0.062 ±  0.006 mmHg-1) was significantly more compliant than middle (0.037 ±  0.003 
mmHg-1) and distal (0.039  0.003 mmHg-1) portions (p<0.001; Figure 3.4A) in control tissues.  
The DM proxim l portion was significantly more compliant than that of the control pro al 
(0.062 -1; p<0.05).  All other comparisons in the other 
g) among control middle (0.032 
±
 0.006 versus 0.046+/-0.006 mmHg
a
pressure ranges (6 to 20 mmH
xim
±
±  0.006 mmHg-1) and distal 
(0.032 -1) and DM middle and distal displaye  statistical significan
 Separating the time points of DM for low-pressure incremental compliance, the 
progressive changes in the disease state were observed (Figure 3.4B).  For within-tissue 
differences at low-pressure compliance, statistical analysis via one-way ANOVA with repeated 
measures indicated that the proximal portions of the 3-week (0.077 
±  0.004 mmHg d no ce.   
±  0.013 mmHg-1) and 5-
week (0.062  0.009 mmHg-1) DM urethras were significantly more compliant than their middle 
(0.048  0.002 versus 0.034  .006 mmHg-1, respectively; p<0.01) and distal (0.042  0.006; 
0.038 -1) portions.  Low pressure compliance also revealed that the proximal and 
middle portions of the 3-week DM urethra were significantly more compliant than control 
proxim  0.013 versus 0.046 
±
 0.005 mmHg
l (0.077 
±
±
a
± ±
± ±  0.006 mmHg-1 ) and m ddle 
(0.032 -1) portions (p <0.05 and p <0.01, respectively), and that middle portions 
of 10-week DM were significantly less pliant than 3-week mid portion (0.030 
 0.002 mmHg , respectively; p<0.01). 
 Middle pressure (6 to 12 mmHg) incremental compliance for the baseline state showed 
no within-tissue differences for either control or DM urethras (Figure 3.5). Proximal, middle, and 
distal areas compared among control (0.011 
, respectively; p<0.05 i
 0.005 
±  0.006 mmHg
com ±
versus 0.048 ± -1
±  0.002, 0.016 ±  0.002, 0.013  0.001 mmHg-1) 
and DM (0.018  0.003, 0.015  0.002, 0.02 
±
± ± ±  0.002) were not significantly different either. 
mpliance values for control (0.007 High-pressure (12 to 20 mmHg) co ±  0.002, 0.008  0.002, 
0.007  0.001 mmHg-1
±
± ) and DM  (0.007 ±  0.001, 0.007 ±  0.001, 0.008 ±  0.001 mmHg-1) 
proximal, middle, and distal segments displayed no within-tissue differences or between DM and 
ontrol (Figure 3.6).   
 
c
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B 
Figure 3.4:  Low pressure incremental compliance (0 to 6 mmHg) values for DM (A) and  
three time points of DM (B) in comparison to control values in the baseline state. Error 
bars represent standard error of the mean. 
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 The middle (Figure 3.5) and higher pressure (Figure 3.6) compliances revealed no 
statistical differences among positions within the specimens of each time point compared with 
the control group.  Comparing proximal positions for middle pressure compliance among 
controls (0.011 ±  0.002 mmHg-1), 3-week (0.017 ±  0.005 mmHg-1), 5-week (0.012  0.001 
mmHg-1), and 10-week (0.025  0.006 mmHg-1), one-way ANOVA indicated a trend where 10-
week DM proximal portions were more compliant than proximal portions of controls (p = 0.06). 
The middle portions and distal portions for, 3-week, 5-week, and 10-week had no significant 
differences among the groups at both middle and high pressure compliances.  Two way ANOVA 
analysis showed that onset of DM played a large role in significant differences found for middle 
pressure incremental compliance. This indicated that 10-week DM was significantly more 
compliant from both 5-week (p = 0.026) and controls (p = 0.021), more specifically for the 
proximal portions.  Two way ANOVA indicated no difference among the groups for high 
pressure incremental compliance.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
±
±
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A 
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Figure 3.5:  Middle-pressure incremental compliance (6 to 12 mmHg) values for DM (A) 
nd three time points of DM (B) both in comparison to control values in the baseline state. 
Error bars represent standard. 
a
 41
 
 
Figure 3.6: High-pressure incremental compliance (12 to 20 mmHg) values for DM (A) an
three time points of DM (B) both in comparison to control values in the baseline state. 
Error bars represent standard e
d 
rror of the mean. 
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 Beta Stiffness values calculated for all three portions of controls (7.3 ±  0.9, 7.8 ±  0.8, 
7.6  0.8) and DM (8.0  0.4, 8.6  0.5, 8.1 ± ± ± ±  0.5) displayed no significant within-tissue 
DM and controls (Figure 3.7).  On
hand differences were found when the time points of DM were compared to controls (Figure 
3.7).  Beta stiffness values for the proximal and middle portions of 5-week DM (9.1  0.5, 9.8 
pliant) than that of 10-week DM (6.9 
differences and no significant differences between 
 0.8; p<0.05)) were significantly stiffer (less 
 the other 
±
± com ±  1.0, 
 0.5; p<0.05).  Beta s ces am
the tissue in any of the groups (Figure 3.7). 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
7.8 ± tiffness showed no significant differen ongst positions within 
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Figure 3.7: Beta Stiffness values for DM (A) and three time points of DM (B) both in 
comparison to control values in the baseline state. Error bars represent standard error of 
the mean. 
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3.2.2 Passive Biomechanics 
 
 
Pressure-diameter curves for healthy urethras showed a nonlinear, exponential curve often 
characteristic of biological tissues (Figure 3.8).  For control tissue, the proximal-to-distal 
compliance gradient - which was also seen in the baseline state (recall Figure 3.2) - became 
statistically significant (p = 0.001), with the proximal significantly more compliant than the mid 
and distal portions.  
 
 
 
 
 
Figure 3.8:  Pressure-diameter curves for the three different positions along the length of 
the urethra. With a proximal-to-distal shift to left, this data suggests that the proximal 
portion is more compliant than both the mid and distal portions. 
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 Comparing each portion separately among groups, the normalized and averaged pressure- 
iameter plots distinguished some differences in the passive state between controls and diabetic 
 had 
me 
 
parisons were made simply between control biomechanical data and all time 
oints of DM as a group. As stated previously, passive data for low pressure incremental 
ompliance (Figure 3.10) indicated within-tissue differences with proximal compared to middle 
and distal portion, and there was a significant difference among dm portions (0.082  0.009, 
0.057  0.003, 0.057  0.004 mmHg-1; p<0.01).  Comparing portions between groups in this 
pressure range, proxim l portions for controls (0.058 
d
urethras at different time points (Figure 3.9). For proximal portions, the 3 and 10-week DM
a more compliant response than control and 5-week. With middle and distal portions, all ti
points of DM displayed a marked shift to the right (i.e. increase in compliance or reduction in
stiffness) compared to controls.   
 Initially, com
p
c
±
± ±
a ±  0.007 mmHg-1) and DM (0.082 ±  0.009 
mmH ) were not significantly different. For the middle portions controls (0.037 
significantly different from DM (p<0.001), and distal portions of controls (0.034  0.005 
mmHg-1) were significantly less compliant, also (p=0.003).  Two-way ANOVA indicated that 
both state and position of the tissue were factors in any differences that occurred (p<0.001); yet, 
there was no significant interaction between the two factors (p=0.96).   
 As with baseline data, DM data was separated into time points 3, 5, and 10-week DM and 
compared to healthy controls in order to study biomechanical changes with the onset of DM. 
Low-pressure compliance for the passive state indicated opposite results than that of baseline.  
That is, for within-tissue differences, the control (0.058 
g-1 ±
±
 0.004) were 
±  0.007 mmHg-1) and 10-week (0.090 
 0.01 mmHg-1) proximal portions were significantly different from middle (0.037  0.003; 
0.055  0.005 mmHg-1, respectively) and distal (0.033 
± ±
± ±  0.004; 0.055 ± 0.008 mmHg-1, 
respectively) portions (p <0.001, p<0.05, respectively), and there was no within-tissue 
ifferences indicated for 3-week and 5-week DM urethras.  Low-pressure incremental 
ompliance indicated trends developed with the proximal portions. Though only closely 
iddle and distal portions 
f controls proved to have significant differences in compliance compared to all time points of 
M. Middle portions of 3-week (0.056 ± 0.006 mmHg-1), 5-week (0.059 ± 0.005 mmHg-1), and 
10-week (0.055 ± 0.005 mmHg-1) DM were more compliant than controls (p=0.009).   
d
c
significant (p=0.095) 3-week and 10-week DM proximal portions were more compliant than 
control and 5-week DM proximal portions. With one-way ANOVA, m
o
D
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Figure 3.9: The average and normalized pressure-diameter response of proximal (top), 
middle (middle) and distal (bottom) portions of 3, 5, and 10-week DM urethras and 
controls in the passive state. 
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The same was found for distal portions of 3-week (0.064 ± 0.006 mmHg-1), 5-week (0.053 ± 
0.006 mmHg-1), and 10-week (0.054 ± 0.008 mmHg-1) DM urethras, as well (p=0.02). Two way 
ANOVA indicated that both position (p<0.001) and onset of DM (p<0.001) had major roles in 
significant differences found, especially between controls and all time points of DM. Our data 
suggests that interaction between these two factors played no role in any observed differences 
(p=0.3; Figure 3.10).  
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Figure 3.10: Low pressure incremental compliance (0 to 6 mmHg) values for combined DM  
(A) and three time points of DM (B)  compared to control values in the passive state. Error 
bars represent standard error of the mean. 
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Middle incremental compliance showed no differences among positions with in the same 
tissue, but proximal (0.009 ± 0.006 mmHg-1) and middle (0.010 ± 0.004 mmHg-1) controls were 
significantly more compliant than proximal (0.006 ± 0.004 mmHg-1) and middle (0.007 ± 0.003 
mmHg-1) DM (p=0.006, p=0.02).  Distals were not significantly different.  Additionally, no 
differences were seen for high-pressure compliances for comparisons between proximal, middle, 
or distal portions (Figures 3.11 and 3.12). 
  For comparisons between separated time points of DM and controls, incremental 
compliance for the middle pressure ranges indicated that no within tissue differences were seen 
among the portions along the length of the urethra in any of the groups. Still, the proximal to 
distal compliance gradient for controls was maintained as proven by the compliance values in the 
bar graph. Actually, this gradient was preserved for high-pressure incremental compliance, as 
well. With the onset of DM, this proximal to distal gradient was no longer present.  Middle 
pressure incremental compliance (Figure 3.11) showed that proximal control (0.055 ± 0.005 
mmHg-1) values were more compliant than 10-week DM (0.005 ± 0.001 mmHg-1) proximal 
(p=0.012). Control and 10-week DM middle portions were found be closely different (p = 0.096) 
with controls more compliant that all time points of DM. Distal portions of each group showed 
no significant difference (p=0.237). Two way ANOVA indicated a loss of position as a factor of 
differences (p = 0.725), but onset of DM was sustained as a significant factor (p<0.001) where 
controls were significantly different from all time points of DM. There was no role of interaction 
between position and onset of DM (p = 0.81). Comparisons for compliance values in the high-
pressure ranges (Figure 3.12) indicated a significant difference (p = 0.023) for proximal portions 
of controls (0.007 ± 0.001 mmHg-1) and 10-week DM  (0.004 ± 0.001 mmHg-1).  Middle 
(p=0.161) and distal (p=0.845) portions of all urethras showed no significant differences among 
each group. As well, a two way ANOVA denoted that both position (p 0.262) and time 
(p=0.181) did not have a role in any variations perceived.  
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iddle pressure incremental compliance (6 to 12 mmHg) values for combined 
DM (A) and three time points of DM (B) compared to control values in the passive state. 
rror bars represent standard error of the mean. 
Figure 3.11: M
E
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Figure 3.12: High-pressure incremental compliance (12 to 20 mmHg) values for combined 
DM (A) and three time points of DM (B) compared to control values in the passive state. 
Error bars represent standard error of the mean. 
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 Beta stiffness values indicated that DM urethras were stiffer than controls in the passive 
state (Figure 3.13A). The only significant comparison was between proximal (10.1 ±  2.9, 12.8 ± 
3.4) portion of controls and DM (p=0.02). Two way ANOVA suggested that the state of the 
tissue (healthy versus diseased) was the only factor which played a role in any significant 
differences.   
 Beta stiffness values in the passive state showed no within tissue differences between 
proximal, middle and distal portions for controls (10.1 ± 0.85, 10.6 ± 0.68, 10.69 ± 0.76; 
p=0.78), 3-week DM (10.2 ± 1.0, 11.8 ± 0.9, 13.7 ± 1.9; p=0.237), 5-week DM (14.4 ± 1.1, 12.7 
± 0.9, 12.3 ± 0.9; p=0.223), and 10-week DM (13.4 ± 1.0, 12.0 ± 1.1, 12.1 ± 1.0; p= 0.21; Figure 
20B).  Comparing the positions of each group, one way ANOVA confirmed a difference in the 
proximal portions (p=0.004). Furthermore, the pairwise comparison indicated that 5 (p=0.009) 
and 10 (p=0.045) week DM were significantly stiffer than controls, and 3-week DM were less 
stiff than 5 (p=0.017) and 10 (p=0.041) week DM.  Two way ANOVA suggests that position was 
not a determining factor in significant differences (p=0.844), but, on the other hand, DM took 
part in significant differences (p=0.007). More specifically, controls were significantly less stiff 
(more compliant) than 5 (p=0.005) and 10 (p=0.029) weeks of DM.  Additionally, there was not 
a statistically significant interaction among the two factors (p=0.21).   
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igure 3.13: Beta Stiffness values for combined DM (A) and three time points of DM (B) 
ompared to control values in the passive state. Error bars represent standard error of the 
ean. 
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3.3 PHARMACOLOGICAL ASSESSMENT 
 
 
With the contractile responses of the DM urethras grouped, there was a significant gradual 
decrease in diameter response to Nω-nitro-L-arginine between control (-2.9 +/- 1.3 %) and DM 
(-0.1 ± 0.4 %) urethras (p=0.04; Figure 3.14).  On the other hand, the maximal contraction to 
phenylephrine (PE-max) for DM (-9.1 ± 2.2 %) urethras appeared to be greater than that of 
controls (-8.2 ± 1.6 %). While this difference was not significant (p=0.8), the same result was 
maintained for the relaxation response to EDTA.  
 
 
 
 
Figure 3.14: Urethral response to Nω-nitro-L-arginine, phenylephrine and EDTA.  The 
rror bars represent SEM. 
 
e
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The control (5.6 ± 1.6 % .4 %).  Additionally, the 
ontrol (-7.4 ± 1.1 %) urethras displayed a stronger maintenance of the contractile response (PE-
vation was a trend (p=0.08).    
 
 
 
 
e 
) relaxation was less than that of DM (8.2 ± 1
c
end) compared to DM (-5.1 ± 2.7 %), although this observation was not significant. 
 Comparing 5 and 10-week time points of DM separately to controls provided a further 
insight to the progressive loss of smooth muscle function, but no significant differences were 
found (Figure 3.15).  Response to the Nω-nitro-L-arginine was progressively abolished at 5-
week (-0.6 ± 0.5 %) and 10-week DM (0.3 ± 0.7 %) compared to the control response (-2.9 ± 1.3 
%), and statistical analysis indicated that this obser
 
Figure 3.15: Urethral response to nitric oxide inhibitor (Nω-nitro-L-arginine), contractil
(PE) and relaxation agents (EDTA).  The error bars represent SEM. 
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For PE, mean values indicate that the maximal response increased by 5-week DM and weakened 
to less than control values by 10-week DM.  Unlike control urethras, DM urethras were unable to 
maintain the contractile response for a period of 20 to 30 minutes.  Finally, the relaxation 
r 
han 400, 
eight loss/ blood glucose greater than 400, and weight loss/ blood glucose greater than 400 
igure 3.16).   
 
 
 
 
    
response increased with 5-week DM (7.9 ± 1.8 %) and even more so with 10-week DM (8.6 ± 
2.3%). The observations of PE and EDTA were also not statistically significant.  
 Due to animal to animal variability with measured weight gain or loss and blood suga
levels (BG) of the diabetic animals, the pharmacological responses were separated into four  
groups: weight loss/ blood glucose less than 400, weight gain/ blood glucose less t
w
(F
Figure 3.16: Urethral response to contractile (PE) and relaxation agents (EDTA).  The 
error bars represent SEM. 
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 Weight loss or gain was dependent on the weight measured during the first three days 
after injection of STZ, which has a maximal three day delay before its effects ensue [40].   
The maximal response to PE was greatest from the groups of animals that gained weight w
BG > 400 (-12.7 ± 4.5%) and lost weight with BG < 400 (-12.3 ± 2.7%).  The animals, which 
lost weight with BG>400, had a contractile response which was significantly less 
ith 
in magnitude 
ght 
is result.   
The amount of time to reach maximal response between controls and DM animals was 
different, as well. The control (4.2 ± 1.1 minutes), 5-week (4.2 ± 1.8 minutes) and 10-week (2.6 
± 4.3 minutes) DM middle urethral response to PE exhibited no significant differences (p=0.78; 
Figure 3.17). On the other hand, the control (8.7 ± 1.4 minutes) EDTA response was  
significantly less than that of 5 (18.9 ± 3.4 minutes) and 10-week (12.1 ± 2.3 minutes) DM.  
 
 
 
 
 
 
 
 
 
than all other groups. From PE-end values, the controls (-7.4 ± 1.1%) appeared to maintain the 
contractile response more than all diabetic groups; yet, this development was not significant. 
Finally, the largest relaxation response from EDTA arose from the group, which gained wei
with BG> 400 (9.8 ± 3.7%), but one-way ANOVA did not reveal a statistically significant 
difference for th
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Figure 3.17: The time to reach maximal response to PE and EDTA for each group. No  
differences were seen for PE, but DM increas
EDTA. 
 
 
 
 
3.4 HISTOLOGICAL RESULTS 
 
 
3.4.1 Smooth Muscle Quantification 
 
  
Representative immunohistochemical staining for smooth muscle α-actin results appear in 
Figure 3.18. The amount of smooth muscle ranged between 15 and 30% dependent upon the 
portion of the urethra (Figure 3.19).  No apparent differences in the amount of smooth muscle 
were noted between control and DM groups. For controls, proximal (21.4 ± 3.5%) and distal 
ed the time for relaxation in response to 
 59
(21.7 ± 4.8%) portions had larger smooth muscle quantities than middle (18.7 ± 2.7%; p =0.8), 
though this was not statistically significant. For 3-week DM, the amount of smooth muscle 
decreased along the length of the urethra proximally to distally (20.8 +/- 5.9%, 19.7 +/- 0.8%, 
14.9 ± 1.1%; p=0.3), but was not significant.   
 
 
 
 
 
igure 3.18: (Left) Smooth muscle alpha actin antibody staining of a proximal urethra 
ed) with the background of Hoescht (blue) at 5x using a Nikon fluorescent microscope. 
(Right) A closer view at (20x) 
 
 and 10-week (p=0.13) DM urethras showed no differences 
f smooth muscle quantities between proximal (15.9 ± 4.1%, 18.9 ± 1.4%), middle (17.1 ± 1.8%, 
0-
 
 
F
(r
  
 
Additionally, 5-week (p=0.12)
o
16.4 ± 2.1%), and distal (21.3 ± 3.3 %, 15.0 ± 0.3%) portions.  However, both 3-week and 1
week DM showed a trend of proximal having more smooth muscle compared to middle and 
distal. 
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Figure 3.19: The amount of smooth muscle alpha actin in the proximal, middle, and distal 
portions of control and DM urethra. Error bars represent standard error.  No significant 
ifferences were noted in any comparisons. 
ount of smooth muscle in the proximal portion decreased, but, 
atistically speaking, the amount of smooth muscle in the proximal and middle portions of the 
ethra remained unaffected by the onset of DM (p=0.63 and p=0.65). In the distal portion, the 
amount
n in the urethra was found abundantly in the lamina propria and surrounds both types of 
smooth muscle components (Figure 3.20).  As with smooth muscle quantification, collagen 
quantification (Figure 3.21) yielded no differences among proximal, middle, and distal portions 
d
 
 
 
Between groups, the average am
st
ur
 of smooth muscle decreased at 3 and 10-week DM compared to controls and 5-week 
indicating a possible trend, but this observation was nearly significant (p = 0.095).   
3.4.2 Collagen Quantification 
 
 
Collage
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in controls (34.8 ± 3.9%, 38.2 ± 2.7%, 45.0 ± 4.1%; p=0.17), 3 (41.5 ± 5.8%, 33.8 ± 3.7%, 40.3 
± 3.8%; p=0.42), 5 (37.2 ± 2.6%, 38.7 ± 3.5%, 43.2 ± 3.4%; p=0.41) and 10 (40.7 ± 2.3, 32.2 ± 
3.6, 38.8 ± 2.9; p=0.15) weeks DM.   The amount of collagen in the urethras averaged between 
35 and 45%.  Among diabetic and control groups, there were no differences among proximal 
(p=0.55), middle (p=0.46), or distal (p=0.62) portions.    
 
 
 
 
 
igure 3.20: (Left) Masson’s trichrome histological stain of a proximal urethra, collagen 
 
 
F
(blue) with muscle (red/brown) at 5x using a light microscope. (Right) A closer view of the
region within the green box of the figure to the left (20x) 
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Figure 3.21: The amount of collagen in the proximal, middle, and distal portions of control 
and DM urethra. Error bars represent standard error.  No significant differences were 
noted in any comparisons. 
 
 
 
3.4.3 Elastin Quantification 
 
 
ventitial area or around the 
musculature, both smooth and striated (Figure 3.22 and 3.23).  The presence of elastin increased 
along the length of the urethra proximally to distally in controls (12. ± 2.8, 16.2 ± 1.3, 17.6 ± 
2.2).  No differences were found among the portions with in the tissue, with the exception of 3-
week DM where the mid portion (12.8 ± 1.4%) had less elastin than the distal portion (18.7 ± 
2.4%; p = 0.05).  While the elastin remained unchanged in the proximal and distal portions, a 
statistically significant decrease could be seen in the middle portion for 10-week DM (10.9 ± 
1.0%) compared to controls (p=0.01). 
 
The amount of elastin was less than that of collagen and smooth muscle, between 15 and 18% on
average, in the urethra, and most elastin was located in the ad
 63
  
 
lack at 5x using a light microscope (Right) A closer view  (20x) 
Note: no background stain was performed. 
     
  
 
 
 
 
 
 
 
 
Figure 3.22: (Left) Weigert’s Recorsin Fuschin histological stain of a proximal urethra, 
elastic fibers, dark purple/ b
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Figure 3.23: The amount of elastin in the proximal, middle, and distal portions of the 
urethra and the effects from DM. Error bars represent standard error. 
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4.0 DISCUSSION 
 
 
 
 
While the bladder has remained the investigative focus of diabetic cystopathy [11-16,20,23], the 
urethra has been largely ignored. A small number of pharmacological studies have been 
performed on the urethra exposed to DM [21,22,25] but, to our knowledge, no studies have 
concentrated on the effects of DM on the biomechanical properties of the urethra.  This 
investigation hypothesized that the biomechanical properties of the urethra - namely, incremental 
compliance and beta stiffness - as well as the pharmacological function of urethral smooth 
muscle are altered due to DM.   
 
4.1 BIOMECHANICAL RESULTS 
s with most biological tissues, the pressure-diameter response was non-linear for both control 
nd DM tissue (Figures 3.2, 3.3, 3.8 and 3.9). Both types of tissue also exhibited creep due to 
eir viscoelastic nature.  More specifically, the response was sigmoidal in shape for the baseline 
ssue and exponential in shape for the passive state.  Most likely, the presence of the smooth 
uscle function in the baseline tissue was responsible for this difference. That is, smooth muscle 
as free to “act” as summarized in Section 2.3, and with both control and DM specimens, the 
rethra would resist initial intraluminal pressures applied (0 to 4 mmHg) with a decrease or 
aintenance in diameter; thus, preventing any distension of the external diameter (Figure 4.1A). 
imilar to these findings, Yalla et al. [44,50] discovered a non-linear pressure-diameter response 
 vivo as well.  Since the urethra is comprised mostly of smooth and striated muscle, collagen 
nd elastin, the initial, easily-distensible phase of the passive curve (also known as the toe region 
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[51]) is attributed to the stretch of the smooth muscle and elastic fibers.  The non-linear region 
here the stiffness of the tissue decreases with increasing distension is attributed to the 
quential uncrimping of the collagen fibers. The relatively indistensible linear region occurs 
when the load is transferred completely to the collagen, causing the collagen fibers to fully 
straighten from their tortuous form at low stress (Figure 4.1B).   
t the baseline state, controls displayed a proximal-to-distal compliance gradient at low 
pressures (0 to 6 mmHg), where the proximal portion was more compliant than middle and distal 
(Figure 3.4 and 3.10). This significant gradient is likely due to the absence of the contribution of 
rendering the urethra a more homogeneous structure.  
The proximal-to-distal compliance gradient seen in the passive state was not verified by 
ny significant differences in the structural analysis of the collagen and elastic fiber components 
f the extra-cellular matrix.  However, perhaps a further analysis utilizing spectrophotometry 
assays to measure actual weights of collagen in the tissue could authenticate this finding.  A 
similar observation was disting in vivo [43,52].  The results 
f this previous study showed that in response to forced dilatation via balloon catheter in vivo, 
ns 
ent 
w
se
A
portions (Figure 3.2). While this observation was not significant in the baseline state at low 
pressures, this proximal-to-distal gradient was significant in passive control tissue at low 
pressures, where the proximal portion was more compliant than middle and distal portions 
the smooth and striated muscle. Since the muscle is “free” to act in the baseline condition, the 
muscle may have been contracting in response to the intralumenal pressure applied; thus, 
a
o
uished in urethras of healthy women 
o
the portion of the urethra near the bladder neck had a significantly higher elastic coefficient and 
dissipated energy compared to the distal portion, thus indicating a urethral stiffening at positio
further from the bladder neck.  While no pharmacological agents were added to inhibit or 
promote muscle contraction, the researchers attributed this finding to the position of the peri-
urethral structures and the involvement of the external urethral sphincter.   
The significant compliance gradient in passive control tissue may be due to the varied 
smooth muscle density along the length of the urethra (i.e. less smooth muscle might be pres
in the proximal portion than in the middle and distal portions).  However, the data from the 
smooth muscle quantification in this study (Figure 3.19) does not support such a variation.  The 
analysis not only displayed no significance of the amount of smooth muscle present in each 
portion, but the proximal and distal portions appeared to have comparable amounts while the  
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 Figure 4.1: Typical proximal pressure-diameter responses which are sigmoidal for baseline
tissue (A) and exponential for passive tissue (B) 
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middle portion had less.  The other reason might be that the amount of collagen, a relatively stiff 
structural protein, in the proximal portion of the urethra was less than that of middle and distal 
portions (Figure 3.21).  Microstructural analysis confirmed these trends, though it was not 
significant.  
DM urethras were also found to have a significant compliance gradient for both baseline 
(especially for 3- and 5- week DM) and passive conditions (especially for 10- week DM).  Since 
the passive state represents mostly the extracellular matrix properties, this would suggest some 
differences in the amount or structure of collagen along the length of the 10-week DM urethra as 
was found with control passive tissue.  However, this was not supported by the data shown in 
Figure 3.22. Instead, microstructural analysis indicated no differences for collagen or elastin 
along the length of the 10-week DM urethra compared to healthy controls. The alternative reason 
for this observation may be the changes in extracellular matrix structure due to DM. It has been 
established that advanced glycation end products (AGEs), which are elevated in DM [59], can 
affect the properties of collagen in a number of ways. It can alter charge profiles, act as an 
oxidizing agent, and form precise supramolecular aggregates [59].  Also, cross-linking AGEs 
that cause the most damaging effects have been related to DM. This type of AGE form 
intermolecular cross links between molecules in the collagen and elastin fibers [60,61].  In 
relation to this possibility, many past studies, including one from our laboratory [91], have 
indicated blood vessel stiffening from the state of DM and attribute these findings to a large 
contribution of AGEs [62-64].  AGEs may also contribute to the progressive significant increase 
in stiffness (decrease in compliance) of the 10-week DM proximal urethra. 
The reason for the proximal portion displaying a higher compliance than middle and 
distal portions of 3- and 5-week DM in the baseline state may be due to regional variations in 
smooth muscle since this observation was not seen in passive 3- and 5-week DM urethras. 
Additionally, the proximal and middle portions of 3-week DM urethras were significantly more 
ompliant at low pressures than that of controls (Figures 3.4 and 3.10).  Either the viscoelastic 
 portions of the urethra with this disease.  
ince compliance measurements are based on the size of the lumen [53], as well as the elastic 
roperties of the urethral wall, the smooth muscle may stimulated into the dilatory state.  A 
major contribution to the increase in low pressure baseline compliance for the proximal portions 
c
properties of the smooth muscle may have been altered due to DM or there may be alterations of 
smooth muscle function in the proximal and middle
S
p
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was the absence of a resistance region displayed by pressure diameter data which was seen in 
controls (Figure 4.1). The failure of smooth muscle to correspond to the intralumenal pressure 
may have been due to smooth muscle cell apoptosis from hyperglycemic conditions [54] or
alteration of 
 
smooth muscle physiology due to diabetic neuropathy [55].  On the other hand, the 
middle
-
t 6 
 
nd 
al 
 
is 
mooth muscle 
present
, 
Analyses of smooth muscle function were performed at the mid point of both control and DM 
 portion for 3-week DM urethras displayed the resistance region in pressure diameter 
curves for low pressure baseline compliance, but mid portion resistance may not have been has 
strong for 3-week DM as for controls. By 6 mmHg, the outer diameter for middle portions for 3
week DM increased 6% more than that of controls.  For increases in low pressure baseline 
compliance between 3-week and 10-week DM, this may also serve as a possible explanation 
where diameter measurements 10-week DM middle portions were similar to that of controls a
mmHg in the baseline state (Figures 3.3-3.5). 
Low-pressure compliance values indicated an increase for DM urethras in middle and 
distal portions in the passive state. Although elastin resides in urethral tissue only in small 
amounts [56], this increase in compliance may be due to a local alteration or increase in the
amount of elastin, which dominates biomechanical behavior at low-pressure.  Studies have fou
that DM induces a change in the amounts of collagen and elastin when compared to norm
tissues [17,57,58].  However, there was a decrease, instead of an increase, for the amount of
elastin between the middle portions of controls, 3 and 10-week DM (Figure 3.23).  While th
may have contributed to the overall stiffness increase seen in middle and high pressure 
compliance and beta stiffness for DM tissues, this does not explain the increase of low pressure 
compliance for DM tissue. The other factor could have been the amount of s
, but the only trend that would support this is the decrease in the quantity of smooth 
muscle in the distal portion of 3- and 10-week DM urethras compared to controls (Figure 3.19)
though this was not statistically significant.   
 
 
 
 
4.2 PHARMACOLOGICAL  FUNCTION OF SMOOTH MUSCLE 
 
 
urethras.  The pharmacological regimen assessed smooth muscle contractility via phenylephrine, 
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a non-selective α1-adrenoceptor agonist, and relaxation via EDTA, a magnesium and calcium 
chelator to inhibit any muscle contraction.  Nitric oxide (NO) release was also examined with th
use of a nitric oxide synthase (NOS) inhibitor, Nω-Nitro-L-arginine, which was applied befo
assessment of phenylephrine.  This preparation ensured maximal smooth muscle contraction.   
In this study, the addition of the NOS inhibitor resulted in a gradual decrease of diame
indicating a tonic relaxation due to the release of nitric oxide.  There could be several possible 
sources of nitric oxide (NO): efferent or afferent nerves, the urothelium, urethral smooth muscle, 
the external urethral sphincter, or endothelial cells in the blood vessels in the urethra [65].  
NOS has been identified in neurons innervating the lower urinary tract.  NOS is most promine
in parasympathetic innervation of the urethra [98].  Functional experiments have shown that 
these nerves have an inhibitory urethral sphinc
e 
re 
ter, 
nt 
ter function [99]. In this case, nerve endings that 
have su
 
ra 
nce 
und to 
 
e passed through in order to rid the system tubing 
of any air bubbles. On the other hand, one factor that may indicate that the urothelium is not  
 
 
 
rvived the isolation process may be the source of the NO release causing an inhibitory 
relaxation of the urethra in response to the increase of intralumenal pressure (0 to 8 mmHg)
during our pharmacological testing.  
As with the endothelial layer of blood vessels, the urothelium can synthesize and release NO.  
Pinna et al. demonstrated that NO dependent relaxations observed in hamster proximal ureth
were diminished following urothelial cell denudation [66].Although the reasons for NO prese
in the urothelium remain a mystery, there could be some relations of the urothelium to the 
function of NO within the endothelium. Since shear stress, as well as stretch, has been fo
stimulate nitric oxide production in endothelial cells [67], the urothelial layer could be stimulated
by shear stress from the actual preparation of tying the tissue onto the tees of the ex-vivo 
perfusion system. That is, the system is filled with media to calibrate pressure and set the 
physiological environment. Once the urethra is tied in, the specimen is exposed to a small 
amount of shear stress when the media must b
 
 
 
 71
  
 
 
 
rtion 
ct 
mooth muscle, but it has been discovered that there is a prominent orientation of cGMP-ir in the 
rethral smooth muscle by NO in guinea pigs (Figure 4.2) [65].  For the striated sphincter, NOS 
ctivity has been evident in the sarcolemma of the intramural striated muscle fibers and the nerve 
bers.  Recent observations suggest that NO has a role in the control of the external urethral 
phincter [68]. The final and most likely source could be the blood vessels, which can be found 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Depiction of the pathway of nitric oxide in urethral smooth muscle or the 
bladder neck (From Mumtaz et al, 2000 [65]) 
 
 
 
responsible for the production of NO, is that it may be injured and impaired due to the inse
of an intralumenal catheter. Of course, from histological observation, this is only true for a 
portion of the specimen. Urethral smooth muscle and external striated sphincter could also be a 
possible source of NO release.  There is no direct evidence that NO is produced by urinary tra
s
u
a
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throughout the urethra. Due to dissection of the urethra and any handling, the blood vessels could 
e releasing NO as a response to injury [67].   
This response to the NO inhibitor was significantly abolished in urethras from severely 
iabetic animals; thus, indicating that NO release was absent in these preparations. First, it must 
e known that STZ is an NO donor, which contributes to the pancreatic destruction of islet cells. 
lthough not likely since STZ was administered many weeks prior to testing, the absence of the 
lease of NO observed in DM urethras could be due to the STZ and not due to the effects of 
M.  In order to make certain that the DM is at fault, the rats that were injected, but had blood 
lucose levels less than 400 could be compared to animals with blood glucose levels greater than 
00 mg/dl (Figure 4.3).   
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Figure 4.3: The STZ injected animals were grouped into high (less than 400 mg/dl) blood
glucose ( n=7) and low (greater than 400 mg/dl) blood glucose (n=7) in order to assess 
whether the absence of NO were due to DM or STZ. (*p<0.05) 
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 The figure conveys that STZ has not altered the effect in low blood sugar animals, which were 
not trul  
ns in the DM rat. 
  ith blood vessels as the source, NO production was found to be reduced in vascular 
smooth muscle and the endothelium exposed to experimental DM [70].  Few studies have 
bserved effects of DM on NO synthesis. Mumtaz et al. (1999) [101] found that DM decreased 
cGMP formation, which is the product of NO releas, in the bladder neck and urethra of the 
rabbit.  In addition, it has been found that urethral NO relaxation is impaired, and the cause may 
be due to lower cGMP formation or increased levels of advanced glycosylation end productus 
(AGE’s), which causes increase crosslinks of the extracellular matrix making it difficult for ion 
channels and membrane bound receptors to become stimulated [71].   Furthermore, it has been 
discovered in vascular smooth muscle that there is a marked increase in superoxide production.  
An interaction between NO and superoxide is very rapid and leads to the inactivation of NO and 
production of an oxidant of peroxynitrite [80].  As a result, this reaction would result in the 
absence of NO, and therefore, to inhibitor response from the NO inhibitor.  
 There are two types of smooth muscle in the urethra, longitudinally-oriented and 
circumferentially-oriented. The longitudinal layer is the inner most layer, and separated from a 
thin layer of collagen, the circumferential layer follows.  Being that the longitudinal direction 
was set at a fixed in vivo length, the laser micrometer could only assess the circumferential 
smooth muscle direction. Whether they act separately to contract and relax the urethra during 
micturition or in a coexisting manner remains highly controversial [72].  The smooth muscle was 
ate 
2-receptors, which causes contraction, and β-receptors, which causes relaxation [73]. Addition 
y diabetic compared to animals of high blood sugar levels. Therefore, the absence of NO
is due to the effects of experimental DM.   
 What could cause this absence of NO release? Depending on the source of the NO, it 
could be due to a number of factors. Nitrergic nerves could be damaged by the diabetic state 
where protein crosslinking by DM induced AGEs can interfere with axonal transport and 
intracellular trafficking by physical blockage.  Studies have shown that in smooth muscle of 
other DM tissues, such as the penis [100], there is a decrease of neuronal NOS due to selective 
damage of nitrergic neuro
W
o
assessed pharmacologically with phenylephrine, an α1-adrenoceptor agonist.  Non-selective 
agonists were not used, such as epinephrine and norepinephrine, because they can also activ
α
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of these non-selective agents would cause a mixed response, and a complete contractile response 
al region [75], which is one of the main reasons why 
e mid
ealthy 
e 
 populations of DM rats: those that severely diabetic 
could be measured [74]. It is possible that α1-adrenoceptors are mainly responsible for 
mediating the effects of sympathetic nerves in the urethra.  Also, this class of receptors has the 
highest population density in the mid urethr
th dle point of the urethra was chosen to test pharmacologically.       
 The contractile response to phenylephrine seemed not to change when basing the 
comparison on controls and 5 and 10-week DM.  Although, a trend was observed that the h
urethras could maintain the contractile response more efficiently than DM urethras.  Due to th
variability of this diabetic rat model, discussed in the limitations (Section 4.5.2), the 
pharmacological data were evaluated on two
(e.g. high blood glucose levels (B.G. ≥  400 mg/dl and dramatic loss of weight) or only mildly 
diabetic (e.g. low blood glucose levels (B.G. ≤ 400 mg/dl and gain and marginal loss of wei
and compared (Figure 3.17). Results showed that the maximal phenylephrine contraction was 
significantly less than all of the other groups signifying that this observation may be correlat
the severity of DM.  This may be due to the hyperglycemic condition brought on by DM’s 
characteristic loss of the production of insulin. Much of this result may be due to the interaction
of the cell surface with the altered extracellular matrix due to non-enzymatic glycosylation 
reactions. AGEs in diabetes have been shown to bind cell surface receptors including the 
receptor for AGEs (RAGE), which has been modified on vascular smooth muscle cells setting 
the stage for excessive tissue damage [76].  Furthermore, studies have shown that AGE’s impair 
arteriolar smooth muscle mechanotransduction by alteration of intracellular calcium handlin
and this occurs in the endothelium, as well [76,77]. This could also be the re
ght) 
ed to 
 
g, 
ason for urethral 
ooth n 
 and 
he 
 the 
 
sm  muscle impaired response to phenylephrine in the severly diabetic state. It has bee
revealed that extracellular and intracellular  calcium release play a role in α1-adrenoceptor 
activated contraction (Figure 4.4) [78].  
The results of this study showed that the magnitude of relaxation induced by calcium
magnesium chelation had no effect in DM urethras compared to controls.  On the other hand, t
amount of  time to reach maximal relaxation was significantly longer for DM urethras.  Like 
with contractililty, this difference may be due to the non-enzymatic glycosylation reactions of
ECM; thus, impairment of ion release of the voltage gated ion channels occurs.  Still, studies on
blood vessels exposed to DM conditions have been conflicting [79].  Much of this may be due 
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different diabetic animal models used, i.e. alloxan versus STZ, or testing at varied times whether 
in the early, intermediate, or late stages of DM.  
 
 
 
 
 
Figure 4.4: A schematic representing the mechanism behind the activation of alpha 1- 
adrenoceptor smooth muscle contraction.  Note: this mechanism is dependent upon both
intra- and extra-cellular calcium levels (From Ruffolo et al. 1991 [78]). 
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4.3 EXPERIMENTAL LIMITATIONS 
 
 
 
 
While these experiments provided much insight to the pathology of diabetic cystopathy, some 
experimental limitations need to be distinguished.  
 
 
4.3.1 Limitations to the Ex-Vivo Experiments  
 
 
 One of the most important disadvantages was the uncertainty and potential error in maintaining 
the urethral in vivo length. For example, the urethra was measured at the time of dissection, but 
the sutures, which ligated the urethra at in vivo length, were untied in order to tie the urethra onto 
the tees of the ex vivo system. With hindsight, it would have been more appropriate to develop 
an adjustable apparatus that could be used at the time of dissection, and versatile in a way that 
the proposed apparatus may fit into the perfusion system.  A similar system has been described 
in the past for vascular segments [30].  Another limitation to the experimental set up was that the 
proximal, middle, and distal portions could not be measured at the same time. The laser could 
only be positioned at one point during testing. Thus, mechanical testing needed to be performed 
at one position at a time and in random order each time in order to avoid any variations in the 
sults due to the strain history effects of biological viscoelastic tissue.  A similar problem 
eded 
The outer diameter was utilized for the calculations of incremental compliance and beta 
iffness.  Conversely, most studies use the mid wall diameter range to calculate beta stiffness 
nd inner diameter (for lumenal volume) to calculate compliance [34].  Under the thin wall 
ssumption, where the thickness is less than .10 of the radius, the outer diameter could be a fit 
easure for these calculations, but this is not the case for the urethra, which has been calculated 
 be a thick walled tube [102]. However, beta stiffness values for the baseline and passive 
roximal urethra are compared to previously calculated values for other tissues [Table 1; 103-
104], and the values are similar in range.  Table 2 represents compliance values for the baseline  
 
re
occurred during pharmacological testing. This not only increased the number of animals ne
for experiments, but also specimen-to-specimen variability.   
st
a
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Table 4.1:  Beta stiffness values for the proximal urethra for  baseline and passive states 
ompared to values calculated for arterial tissues in past literature.  
BETA STIFFNESS VALUE 
c
 
 
TISSUE SPECIMEN 
 
 
Baseline Control Proximal Urethra  
 
7.31  ±  0.89 
 
 
Passive Control Proximal Urethra 
 
10.00 ±  0.86 
 
Human Common Carotid Artery (in vivo) 
[103] 
10.30  ± 0.05 
 
Passive Rat Aorta [104] 
 
1.4  ± 0.4 
 
 
 
Table 4.2:  Compliance values for low (0-6 mmHg), middle (6-12 mmHg), and high (12-20 
mmHg) pressure compliance for the proximal urethra compared to that calculated in past 
 PRESSURE PRESSUR
 
 
 
literature for passive porcine coronary arteries 
 
 
 
SPECIMEN 
LOW 
(mmHg ) 
MIDDLE 
E 
(mmHg ) 
HIGH 
PRESSURE 
(mmHg ) 
TISSUE COMPLIANCE 
-1
COMPLIANCE 
-1
COMPLIANCE 
-1
 
Baseline Control 
 
 
 
 
 
 
 
Proximal Urethra 0.046  ±  0.006 0.011  ±  0.002 0.007  ±  0.002 
 
Passive Control 
 
 
 
 
 
 
 
Proximal Urethra 0.059  ±  0.007 0.010  ±  0.001 0.007  ±  0.001 
    
Passive Porcine 
Coronary 
 
3.086  ±4.473*10-4 
 
0.718 ±  5.522*10-5 
 
0.426  ±  5.020*10-8 
     (at 50 mmHg) 
Arteries [105] 
 
 
     (at 10 mmHg) 
 
     (at 30 mmHg) 
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 and passive pr d to values previously calculated for porcine coronary 
arteries [ t only be due to the use of outer diameter versus 
inner diameter, but different pressure ranges for low, middle, and high pressure compliance 
values we data is not shown,  distal urethral 
compliance and beta stiffness values exhibited the same comparisons, as the proximal urethra 
value
Another assessm at was neglected was the accuracy of measurement. For future 
studies propogation of error analyses will be performed in order to assess rror in the results. The 
analyses that w ed in Appendix B.   
 For future experiments, one might also consider altering the system so that the urethra is 
xposed to continuous flow, yet minimal flow (approximately 1.5 ml/min).  The system used in 
was the adventitial bathing media.  As a result, the tissue may not have received sufficient gas 
balance or nutrients.  This may have contributed largely to any inconsistencies seen in the 
functional data.  Another concern dealing with dissolved gases may have been another limitation. 
Although the media was bubbled with an oxygen m inutes and the urethra was 
placed in a conical tube fill ate spo
transportation time was 30 minutes.  Tissue viability is a limitation to ex vivo systems, also.  
This ribute to pos ble variations for the biomechanical and functional results. 
Kwon et al. [46] found that urethral strips exposed to anoxic conditions exhibited an immediate 
decrease of contractile response to phenylephrine.  Steps should be taken to understand affects 
on the healthy tissue from factors, such as isolat n of the tissue, durat n of time after excision, 
time in the perfusion system, and distension of the tissue.  This may be achieved with the use of 
a live/dead stain to assess necrosis or assessment of lactate dehydrogenase, which indicates the 
amount o  by t e  c  
cell.   
Other limitations relate to the ex vivo nature of the experiments.  The urethra is a highly 
oximal urethra compare
105].  These inconsistencies may no
re used, as well.  Although the the middle and
s.    
ent th
 e
ill be performed are deriv
e
this work was set up so that the distal end was clamped off to allow application of intraluminal 
pressure.  With this approach, the media contained within the urethra was not being circulated as 
ixture for 20 m
ed with the xygeno d media dur g tranin rt, the average 
 obstacle may cont si
io io
f cell death he release of lactate d hydrogenase from the ytosol of the damaged
 
innervated structure involving both somatic (external striated sphincter via pudendal nerve) and 
autonomic (sympathetic and parasympathetic) nervous systems.  By excising the urethra and 
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testing it ex vivo, all neural input to the urethra is eliminated, except for possible spontaneous 
release of transmitter from intramural nerve terminals. Future work might examine the effects of 
electrical stimulation to provide a model of the urethra that is closer to its in vivo environment 
and to maintain the integrity of the nerve tissue. Also, the urethra is composed of both 
longitu
t the urethra became largely 
 
cribed 
ly error 
l 
, 
 to 
he 
 
re 
dinally- and circumferentially- oriented muscle. However, the laser micrometer can assess 
only circumferential contractile response, but longitudinal contraction also plays a large role in 
urethra functionality. As evidence of this, it was observed tha
elongated and kinked within the experimental system once it completely relaxed with the 
addition of EDTA. A suggestion to solve this problem would be to attach two force transducers 
to the tees and connect via A/D conversion board to the computer. Thus, the longitudinal tension
and relaxation could be measured with the addition of each pharmacological agent, as well as the 
circumferential response.   
 Finally, another limitation to this study involved the application of pressure. As des
in Section 1.4, a reservoir filled with media 199 attached to a graduated ringstand was manually 
displaced to apply intralumenal pressure. While much care was taken to calibrate each 
graduation to increments of 2 mmHg using a water manometer, there still was more like
of achieving exact increments of 2 mmHg. Also, by using manual displacement, the 
preconditioning regimen could only be performed at a an approximate maximal rate of 0.5 Hz. 
Much faster strain rates are typically employed for mechanical testing of soft biological tissues 
[92,93].  An automated system involving a computer controlled stepper motor could possibly 
solve this problem, and could also allow the application of the pressure in smaller increments (1 
mmHg).  
 
 
4.3.2 Limitations to Microstructural Analysis 
 
 
Microstructural quantification of the tissue components did not agree with the biomechanica
findings. But, the techniques used were not sensitive and had their disadvantages.  First
cryosectioning produces some voids in the tissue. The purpose of subjecting the tissue
ascending sucrose solutions was to provide a ‘cryoprotectant’ for the tissue before freezing t
tissue for sectioning. However, this tissue can still exhibit freeze-induced damage, including
local disruption  by ice crystals, thus producing holes and affecting measurement of the enti
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urethral cross sectional area. Secondly, while immunohistochemistry is highly specifi
use of antibodies, results from histological staining are quite varied depending on the type of 
animal tissue and method of fixation.  Another disadvantage is that methods used for Masson’
trichrome stain and Weigert’s resorcin fuschin were very sensitive to the washing times, s
times, dehydration times, and clearing times. Holes seen in the tissue could also have 
result of the many washes required for the immunohistochemical and histological methods. Fo
the future, analyses using enzymatic digestions should be considered, as well as methods 
involving three dimensional reconstruction. 
 
c with the 
s 
taining 
been a 
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c activity 
t 
l 
rats, such effects took much longer (on the order of weeks) before they were 
oticeable. While the rats in this study that were deemed diabetic did meet the blood glucose 
ty. The blood glucose levels ranged from <300 to 
55 mg/dl in those DM rats which had this measurement made.  Much of this variability was 
4.3.3 Limitations of the Diabetic Rat Model  
 
Rakieten et al. (1963) [38] were the first to report that streptozotocin exerts diabetogeni
in rats, amongst other animals.  Since then, this diabetic animal model has been largely used to 
replicate type I DM.  Unfortunately, the experience with this particular model was no
repeatable.  Depending on the dosage, studies claim that signs of DM, e.g. high blood glucose 
levels, take effect 8 to 48 hours post STZ induction [38, 47-49].  The dose for these experimenta
studies was on the higher end of that typically used (65 mg/kg), but only a portion of the rats 
exhibited symptoms of STZ-induced DM (e.g. soft fecal matter and weight loss).  For the other 
portion of 
n
criteria (>300 mg/dl), there was much variabili
5
likely due to the vehicle that was used to administer the drug and its preparation. The STZ was 
dissolved in saline and made fresh immediately before induction.  Although this method has 
been previously used [85,89], most studies dissolved STZ into citrate buffer (pH adjusted to 4.5) 
[85].  Since STZ has an extremely short half-life (15 minutes), the method described may aid the 
stability of the drug and provide the more consistency vis-à-vis blood glucose level with this 
experimental diabetic model.  Thus, while it was certain that the DM rats used here were diabetic 
(i.e. they exhibited all of the characteristics summarized in Section C.1), there was no certainty 
as to whether the rats were exposed to exactly 3, 5, or 10-week DM since blood glucose levels 
were measured only at those times following STZ administration.   
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5.0 CONCLUSIONS AND FUTURE WORK 
 
 
 
iabetes mellitus is the leading cause of peripheral neuropathy in the western world [86].  
 has been 
diameter 
rs 
th 
ssue fibers.  These methods 
ave some inadequacies as described in Section 4.3.2.  As described previously in Sections 4.1 
nd 4.2, DM has been associated with advanced glycation endproducts (AGEs) and reactive 
oxygen species (ROS).  As with the vasculature, oxidative stress may cause cellular damage and 
 
D
Cardiovascular, gastrointestinal, and neurological systems, to name a few, are seriously 
damaged, and patients with DM suffer health problems leading to a comprimising lifestyle.  A 
dysfunctional bladder has been the focus of diabetic cystopathy, and not much research
aimed at an understanding of the role of the urethra in this voiding dysfunction.  The experiments 
described here have attempted to answer the biomechanical and functional changes due to the 
onset of this disease.   
 First, a biomechanical testing regimen was implemented to assess the linear elastic 
properties of the urethra in both the diseased and healthy states. By gaining pressure vs. 
data ex vivo, both the beta stiffness and compliance were quantified and compared. From the 
biomechanical data, the first conclusion stands that significant stiffening occurs with the onset of 
DM, most markedly in the proximal portion.  Additionally, increased passive compliance occu
in DM animals at the middle and distal portions at low pressures. These changes in 
biomechanical properties may reflect the alterations of three primary tissue constituents: smoo
muscle (longitudinally- and circumferentially- oriented), collagen, and elastin. With an increase 
in beta stiffness and decrease in middle and high pressure compliance values, it is likely that 
collagen remodeling is a consequence of DM.  Likewise, a significant increase in low 
compliance for DM specimens could represent derangements in elastin that is present, as well.  
Unfortunately, with the exception of the decrease of elastin in the mid portion of 10 week DM 
specimen, histological analyses described here did not reveal any significant changes in the 
amount of any tissue consituent or in the orientation of connective ti
h
a
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AGEs are known to initiate connective tissue cro slinking. Histological methods for collagen and 
elastin could not reveal th n present, and smooth 
muscle alpha actin staining was not capable of a essing cellular damage. It would be important 
to assess any increase in the amount of varied collagen types.  It is well established that collagen 
bril diameters become enlarged from diabetes [94], but it has also been established that there 
tic 
ations in 
ens. Similar to blood vessels, nitric oxide release was absent for DM 
ecim ests 
d to the 
as 
 role the 
s
is type of alteration or different types of collage
ss
fi
are increased amounts of different types of collagens which can indicate alterations of diabe
tissues down to the cellular level. Renal, hepatic, and cardiac tissues have exhibited alter
cell production of collagens type I and III indicating that DM may cause changes in cell 
phenotype [95,96,97].  Further work in the area must be carried out in order to assess these 
possibilities. 
 A pharmacological assessment of mid urethral smooth muscle was performed on both 
control and DM specim
sp ens due to the fact that there was no response to the NO inhibitor.  This finding sugg
that DM might cause an impairment of urethral relaxation.  In agreement with this, it was 
observed that the DM urethra endured a significantly longer relaxation period than controls, 
although the magnitude of relaxation was unaffected (Figures 3.14-3.17).  EDTA is a calcium 
and magnesium chelator indicating that there might be impaired extracellular calcium release. 
Finally, phenylephrine response was also impaired, but this factor was largely relate
severity of the diabetic state of the animal, and the extent of the blood glucose levels. For high 
blood glucose levels, the maximal contraction in response to phenylephrine stimulation was 
significantly impaired. However, this becomes a question of whether or not this discrepancy w
due to the state of DM or the state of hyperglycemia, and if not either, how much of   a
two play in this damage. To determine this, pharmacological assessments should be performed 
on the urethras of sucrose fed animals.  Additionally, it would also be important to assess the 
effects of other smooth muscle contractile agents in order understand the portion of the α1-
adrenoceptor pathway that is damaged.   
 Clearly, the urethra is considerably affected structurally and functionally by the state of 
DM.  Future studies addressing each of the limitations summarized in Section 4.4 should be 
considered. Efforts should also be made to relate these studies to in vivo experiments of DM and 
sucrose-fed control animals, as well. Additionally, ex-vivo biomechanical and pharmacological 
assessments should compared with assessments made in vivo, such as leak point pressure tests 
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and urodynamic analysis.  Correlating these comparisons with protein assays and gene or protein
analyses will further aid the understanding of the tissue remodeling that appears to occur in the 
lower urinary tract from DM, and pave the way for future therapies for diabetic cystopathy.  
Furthermore, enhancing our comprehension of the pathogenesis of voiding dysfunction in DM 
may ultimately help in developing a therapy for these patients who suffer from lower urinary 
tract dysfunction, potentially serving hope for a better lifestyle and a promising future.  
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APPENDIX A. INDIVIDUAL DATA 
 
 
 
 
A.1 CONTROL DATA 
 
.1.1 Baseline State 
 
Figure A.1: Pressure-diameter data for proximal, middle, and distal portions of control 
urethras in the baseline state 
 
A
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Figure A.2: Pressure-diameter data for proximal, middle, and distal portions of control 
urethras in the baseline state. 
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Figure A.3: Pressure-diameter data for proximal, middle, and distal portions of control 
urethras in the baseline state 
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Figure A.4:  Low, middle, and high pressure compliance data for proximal, middle, and 
 urethras in the baseline state 
 
 
 
 
 
 
distal portions of control
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igure A.5: Low, middle, and high pressure compliance data for proximal, middle, and 
istal portions of control urethras in the baseline state 
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Figure A.6: Low, middle, and high pressure compliance data for proximal, middle, and 
distal portions of control urethras in the baseline state 
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igure A.7: Beta stiffness data for proximal, middle, and distal portions of control urethras 
 
 
 
 
 
 
 
 
 
 
 
F
in the baseline state 
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igure A.8: Beta stiffness data for proximal, middle, and distal portions of control urethras 
 the baseline state 
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Figure A.9: Beta stiffness data for proximal, middle, and distal portions of control urethras 
in the baseline state 
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A.1.2 Passive State 
 
Figure A.10: Pressure-diameter data for proximal, middle, and distal portions of control 
 
 
 
 
 
 
 
 
 
 
 
 
 
urethras in the passive state 
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 urethras in the passive state 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure A.11: Pressure-diameter data for proximal, middle, and distal portions of control 
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Figure A.12: Pressure-diameter data for proximal, middle, and distal portions of control 
urethras in the passive state 
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igure A.13: Low, middle, and high pressure compliance data for proximal, middle, and 
istal portions of control urethras in the passive state 
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Figure A.14: Low, middle, and high  pressure compliance data for proximal, middle, and 
distal portions of control urethras in the passive state 
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Figure A.15: Low, middle, and high  pressure compliance data for proximal, middle, and 
distal portions of control urethras in the passive state 
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igure A.16:  Beta stiffness data for proximal, middle, and distal portions of control 
rethras in the passive state 
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Figure A.17: Beta stiffness data for proximal, middle, and distal portions of control 
rethras in the passive state 
 
u
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 Figure A.18: Beta stiffness data for proximal, middle, and distal portions of control 
urethras in the passive state 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 102
A.1.3 Pharmacological Data for Control Urethras  
 
 
 
igure A.19: Pharmacological data representing decrease and increase of the outer 
iameter of the middle portion of control urethras 
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Figure A.20: Pharmacological data representing decrease and increase of the outer 
diameter of the middle portion of control urethras 
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Figure A.21: Pharmacological data representing decrease and increase of the outer 
diameter of the middle portion of control urethras 
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Figure A.22: Pharmacological data representing decrease and increase of the outer 
diameter of the middle portion of control urethras 
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Figure A.23: Pharmacological data representing decrease and increase of the outer 
diameter of the middle portion of control urethras 
 
 
 
 107
A. 2  3-WEEK DM DATA 
 
 
A.2.1 Baseline Data 
 
 
 
 
Figure A.24: Pressure-diameter data for proximal, middle, and distal portions of 3 week 
DM urethras in the baseline state 
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 Figure A.25: Pressure-diameter data for proximal, middle, and distal portions of 3 week 
DM urethras in the baseline state 
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igure A.26: Low, middle, and high  pressure compliance data for proximal, middle, and 
 
 
F
distal portions of 3 week DM urethras in the baseline state 
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Figure A.27:  Low, middle, and high  pressure compliance data for proximal, middle, and 
distal portions of 3 week DM urethras in the baseline state 
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igure A.28: Beta stiffness data for proximal, middle, and distal portions of 3 week DM 
rethras in the baseline state 
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 igure A.29:  Beta stiffness data for proximal, middle, and distal portions of 3 week DM 
rethras in the baseline state 
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A.2.2 3-week DM Passive Data 
 
 
 
 
 
Figure A.30: Pressure-diameter  data for proximal, middle, and distal portions of 3 week 
DM urethras in the passive state 
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 igure A.31: Pressure-diameter  data for proximal, middle, and distal portions of 3 week 
M urethras in the passive state 
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gh pressure compliance  data for proximal, middle, and 
distal portions of 3 week DM urethras in the passive state 
 
 
Figure A.32: Low, middle, and hi
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Figure A.33: Low, middle, and high pressure compliance  data for proximal, middle, and 
distal portions of 3 week DM urethras in the passive state 
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 igure A.34: Beta stiffness  data for proximal, middle, and distal portions of 3 week DM 
rethras in the passive state 
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Figure A.35: Beta stiffness  data for proximal, middle, and distal portions of 3 week DM 
urethras in the passive state 
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A.3  5-WEEK DM DATA 
 
 
A.3.1 Baseline State 
 
 
 
Figure A.36: Pressure-diameter data for proximal, middle, and distal portions of 5 week 
DM urethras in the baseline state 
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igure A.37: Pressure-diameter data for proximal, middle, and distal portions of 5 week 
M urethras in the baseline state 
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Figure A.38: Pressure-diameter data for proximal, middle, and distal portions of 5 week 
DM urethras in the baseline state 
 
 
igure A.39: Low, middle, and high pressure compliance data for proximal, middle, and 
istal portions of 5 week DM urethras in the baseline state 
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Figure A.40: Low, middle, and high pressure compliance data for proximal, middle, and 
distal portions of 5 week DM urethras in the baseline state 
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Figure A.41: Low, middle, and high pressure compliance data for proximal, middle, and 
distal portions of 5 week DM urethras in the baseline state 
 
 
 
igure A.42: Beta stiffness data for proximal, middle, and distal portions of 5 week DM 
rethras in the baseline state 
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Figure A.43: Beta stiffness data for proximal, middle, and distal portions of 5 week DM 
urethras in the baseline state 
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 Figure A.44: Beta stiffness data for proximal, middle, and distal portions of 5 week DM 
urethras in the baseline state 
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A.3.2  Passive State  
 
 
 
ek 
 
 
igure A.45: Pressure-diameter data for proximal, middle, and distal portions of 5 we
M urethras in the passive state 
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Figure A.46: Pressure-diameter data for proximal, middle, and distal portions of 5 week 
DM urethras in the passive state 
 
 
 
Figure A.47: Low, middle, and high pressure mpliance data for proximal, middle, and 
distal portions of 5 week DM urethras in the passive state 
co
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Figure A.48: Low, middle, and high pressure compliance data for proximal, middle, and 
distal portions of 5 week DM urethras in the passive state 
 
 
 
 
 
 
 129
 Figure A.49: Low, middle, and high pressure compliance data for proximal, midd
distal portions of 5 week DM urethras in the passive state 
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Figure A.50: Beta stiffness data for proximal, middle, and distal portions of 5 week DM 
rethras in the passive state 
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igure A.51: Beta stiffness data for proximal, middle, and distal portions of 5 week DM 
rethras in the passive state 
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A.3.3  Pharmacological Data for 5-week DM Urethras 
 
 
 
igure A.52: Pharmacological data representing decrease and increase of the outer 
diameter of the middle portion of control urethras. Blood glucose levels were (top) 484 
mg/dl and (bottom) 462 mg/dl 
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Figure A.53: Pharmacological data representing decrease and increase of the outer 
12 
 
 
 
diameter of the middle portion of control urethras. Blood glucose levels were (top) 3
mg/dl and (bottom) 300 mg/dl 
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igure A.54: Pharmacological data representing decrease and increase of the outer 
iameter of the middle portion of control urethras. Blood glucose levels were (top) 392 
 
F
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mg/dl and (bottom) 396 mg/dl 
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Figure A.55: Pharmacological data representing decrease and increase of the outer 
diameter of the middle portion of control urethras. Blood glucose level: 458 mg/dl 
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A.4  10-WEEK DM DATA 
 
A.4.1 Baseline Data 
 
 
 
 week 
M urethras in the baseline state 
 
 
 
 
 
 
 
 
 
Figure A.56: Pressure-diameter data for proximal, middle, and distal portions of 10
D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 136
 
 
 
igure A.57: Pressure-diameter data for proximal, middle, and distal portions of 10-week 
M urethras in the baseline state 
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Figure A.58: Pressure-diameter data for proximal, middle, and distal portions of 10-week 
DM urethras in the baseline state 
 
  
 
 
Figure A.59:  Low, middle, and high pressure compliance data for proximal, middle, and 
distal portions of 10-week DM urethras in the baseline state 
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Figure A.60: Low, middle, and high pressure compliance data for proximal, middle, and 
distal portions of 10-week DM urethras in the baseline state 
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Figure A.61:  Low, middle, and high pressure compliance data for proximal, middle, and 
distal portions of 10-week DM urethras in the baseline state 
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Figure A.62: Beta stiffness data for proximal, middle, and distal portions of 10-week DM 
rethras in the baseline state 
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Figure A.63: Beta stiffness data for proximal, middle, and distal portions of 10-week DM 
urethras in the baseline state 
 
 
 
igure A.64: Beta stiffness data for proximal, middle, and distal portions of 10-week DM 
rethras in the baseline state 
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A.4.2  Passive Data 
 
 
 
 
 
Figure A.65: Pressure-diameter data for proximal, middle, and distal portions of 10-week 
DM urethras in the passive state 
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Figure A.66: Pressure-diameter data for proximal, middle, and distal portions of 10-week 
DM urethras in the passive state 
 
 
 
 
 
 
 
  
Figure A.67: Low, middle, and high pressure compliance data for proximal, middle, and 
istal portions of 10-week DM urethras in the passive state 
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Figure A.68: Low, middle, and high pressure compliance data for proximal, middle, and 
distal portions of 10-week DM urethras in the passive state 
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Figure A.69: Beta stiffness data for proximal, middle, and distal portions of 10-week DM 
 
urethras in the passive state 
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Figure A.70: Low, middle, and high pressure compliance data for proximal, middle, and 
distal portions of 10-week DM urethras in the passive state 
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A.4.3  Pharmacological Data 
 
 
d increase of the outer 
iameter of the middle portion of control urethras. Blood glucose levels were (top) 540 
g/dl and (bottom) 408 mg/dl 
 
 
 
 
Figure A.71: Pharmacological data representing decrease an
d
m
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Figure A.72: Pharmacological data representing decrease and increase of the outer 
iameter of the middle portion of control urethras. Blood glucose levels were (top) 479 
mg/dl and (bottom) 368 mg/dl 
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igure A.73: Pharmacological data representing decrease and increase of the outer 
iameter of the middle portion of control urethras. Blood glucose levels were (top) 480 
mg/dl and (bottom) 399 mg/dl 
F
d
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Figure A.74: Pharmacological data representing decrease and increase of the outer 
diameter of the middle portion of control urethras. Blood glucose levels were (top) 479 
mg/dl and (bottom) 368 mg/dl 
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igure A.75: Pharmacological data representing decrease and increase of the outer 
55 
 
F
diameter of the middle portion of control urethras. Blood glucose levels were (top) 3
mg/dl and (bottom) 282 mg/dl 
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APPENDIX B. PROPOGATION OF ERROR ANALYSIS 
 
 
 
 The following error analysis to be performed is established from that of previous studies 
[106].  Before assessing the propogation of error in calculated quantities, the uncertainty in the 
directly measured parameters used in the calculations must first be determined or estimated. 
The system will be set up with a normal rat urethra tied in to the ex vivo system.  A 
mercury manometer will be used to measure each maximum and minimum pressure value for 
each pressure range used to calculate low (0-6mmHg), middle (6-12 mmHg), high (12-20 
mmHg) pressure compliance values.  This will be repeated several times.  The resulting 
measurements will be averaged and a standard deviation will be computed.   
 Next, the laser micrometer will be used measure proximal, middle, and distal outer 
diameters of the urethra, separately.  Measurements will be repeated at low, middle, and high 
pressure ranges.  Values for maximum and minimum diameter values will be averaged and 
standard deviations will be computed.   
In summary, the following uncertainties will be needed for to evaluate the propogation of error 
for compliance: 
σPmax = uncertainty value for maximum pressure 
σPmin = uncertainty value for minimun pressure 
σDmax = uncertainty value for maximum outer diameter 
σDmin = uncertainty value for minimum outer diameter 
 
After determination of uncertainties, the next step will be to compute the propogation 
error for the compliance calculation.  Below are the required equations: 
 Equation B.1: 
 
 
 Error analysis is based on
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Equation B.1 
 
 
 
 
here, λ is a computed quantity and α, β, γ are either a directly measured quantity  or a previous 
calculated  quantity, each with a known uncertainty, σ.  The differentials for λ with respect to α, 
, and γ
sed 
to asse
2
2
,
2
2
,
2
2
,
2
γ
βα
β
γα
α
γβ
λ σγ
λσβ
λσα
λσ 


+


+

=
d
d
d
d
d
d
 
w
β  are the average uncertainties, which are usually taken as 2 standard deviations for 95% 
confidence limits.  Squared terms are appropriate for treatment of random errors.   
 Simple addition (Equation B.2) and multiplication (Equation B.3a and B.3b) will be u
ss the error in various calculated quantities.  
 
 
 If  λ =  α + β + γ, then; 
 
1,1,1 === γ
λ
β
λ
α
λ
d
d
d
d
d
d
 
Incorporating these values into Equation
 
 A-1, the resulting equation is reduced to Equation B.2: 
 
 
 
 
 
his relation will be used to describe the propogation of error for the differences between 
maxim
If  λ =  α βγ, then; 
 
Equation B.2 
2222 σσσσ ++= γβαλ
T
um and minimum pressure measurements, as well as for respective diameter 
measurements.  
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αβγ
λαγββγα === d
d
dd
,,  
λλ dd
 
Incorporating these values into Equation A-1, the resulting is reduced to Equation B.3a: 
 
 
Equation B.3a  
 
 
quation B.3b 
 
 
This relation will be used to describe the propogation of error when using the pressure-diameter 
relation, compliance.  For the compliance equation (Equation 2.2), the error will need to be 
 
 
 
For further simplification, this equation may be divided through by λ2 =  α2 β2 γ2 
( ) ( ) ( ) 2222222 γβαλ σαβσαγσβγσ ++=
yielding Equation A-3b: 
 
E
 2222 %%%% γβαλ σσσσ ++= 
calculated for the differences in pressure and diameter, separately. For pressure, ∆P = Pmax - Pmin: 
( )2min2max PPP σσσ +=  
or diameter,  ∆D = Dmax - Dmin : 
 
F
( )2 min2 max DDD σσσ +=  
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and to complete for the entire diameter relation, 
( )
Min
MinMax
D
DD −
 :  
 







+


= 2
2
min
2
2
min
11
D
D
D
D
Dfinal σσσσσ  
 
The final calculation that will provide the propogation of error for th compliance calculation 
(σC), Equation B.4: 
 
quation B.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
e 
 
E
 
 
2
2
1
Dfinal
P
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